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ABSTRACT 
Background: Maternal obesity is a risk factor for gestational diabetes and other 
adverse pregnancy outcomes, but the body fat distribution may be a more 
important risk factor than body mass index. Pregnancy is an insulin resistant 
state and more so, in obese women. Metformin could be beneficial in obese 
pregnant women due to its insulin sensitizing action. The aims of this study are 
to investigate visceral fat mass as a risk factor for gestational diabetes (VFM 
study), to develop a mathematical model for the prediction of gestational 
diabetes in obese women (VFM study) and to examine the effect of metformin 
on pregnancy outcomes in obese non-diabetic women (MOP Trial). 
Methods and Results:  
VFM study: The body composition of 302 obese pregnant women was 
assessed using bioelectrical impedance. A mathematical model to predict 
gestational diabetes using machine learning was developed using visceral fat 
mass which is a novel risk factor in addition to conventional risk factors. 72 of 
the women developed gestational diabetes (GDM). These women had higher 
visceral fat mass. Women with a baseline visceral fat mass ≥ 75th percentile, 
had a 3-fold risk of subsequent gestational diabetes. The mathematical model 
predicted gestational diabetes with an average overall accuracy of 77.5% and 
predicted birth centile classes with an average accuracy of 68%. According to 
the decision tree developed, VFM emerged as the most important variable in 
determining the risk of GDM and a VFM < 210 was used as the first split in the 
decision tree. 
MOP Trial: 133 obese pregnant women were randomised to either metformin or 
placebo. The pregnancy outcomes were compared in both groups. Insulin 
resistance was measured in all women. 118 women completed the trial. 
Metformin did not reduce the neonatal birth weight z-score, which was the 
primary outcome of the trial or the incidence of large for gestational age babies. 
However, metformin therapy significantly reduced gestational weight gain, 
reduced the pregnancy rise in visceral fat mass, and attenuated the expected 
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physiological rise in insulin resistance at 28 weeks gestation. However, this did 
not result in an overall significant reduction in the incidence of gestational 
diabetes. There was a trend towards a reduced incidence of gestational 
diabetes in women with high baseline insulin resistance randomised to 
metformin. 
Conclusions: Visceral fat mass is a novel risk factor for gestational diabetes. 
The mathematical model successfully predicted gestational diabetes. Metformin 
reduced gestational weight gain and insulin resistance but did not lower the 
median neonatal birth weight or reduce the incidence of GDM. 
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1     INTRODUCTION 
1.1 Diabetes Mellitus 
1.1.1 Definition 
Diabetes mellitus (DM) can be defined as a state of chronic hyperglycaemia 
sufficient to cause long-term damage to organs and tissues including  retina, 
kidney, nerves and blood vessels [1]. It is thought to be due to a varying 
combination of insufficient production of insulin and /or resistance to the glucose 
lowering action of insulin [1]. The word diabetes is derived from a Greek word 
meaning a “siphon”. The 2nd century AD Greek physician Aretus the 
Cappadocian, named this condition diabetes as he observed that these patients 
“passed water like a siphon”, referring to polyuria observed in patients with 
untreated DM [2].  
DM has been known since about 1500 BC, when Hindu scholars described a 
condition wherein a patient would present with symptoms of polydipsia, polyuria 
and production of sweet urine which would attract flies and ants. These patients  
would also have signs of wasting [3]. 
1.1.2 Aetiological classification of diabetes mellitus 
DM is now classified depending on the pathologic process that leads to 
hyperglycaemia, as opposed to earlier when it was classified depending on age 
of onset and treatment required [4]. The two broad categories of diabetes are 
designated as type 1 (T1DM) and type 2 (T2DM) [4]. 
Type 1 diabetes mellitus 
T1DM is caused by an autoimmune process which selectively causes 
pancreatic β cell destruction leading to deficiency of insulin [1]. T1DM has long 
been called “juvenile diabetes” because of the more frequent and 
straightforward diagnosis in children. However, a majority of the individuals with 
T1DM are adults [5]. 
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Type 2 diabetes mellitus 
T2DM is characterised by a combination of insulin resistance, impaired insulin 
secretion and increased glucose production in varying proportions [4]. Patients 
usually have a period of abnormal glucose tolerance which may be  impaired 
fasting glucose (IFG) or impaired glucose tolerance (IGT) for a few years before 
the diagnosis of T2DM [4]. 
Other specific types of diabetes mellitus 
Genetic defects of β cell development 
Maturity onset diabetes of the young (MODY) is the most common form of 
monogenic diabetes, accounting for 2-5% of diabetes. MODY is characterised 
by a primary defect in insulin secretion and hyperglycaemia, non-ketotic 
disease, monogenic autosomal dominant mode of inheritance, age at onset less 
than 25 years, and lack of auto-antibodies. The diagnosis can be suspected by 
careful clinical evaluation, but genetic analysis is essential for subtyping [6]. 
Genetic defects in insulin secretion  
Mutations in the insulin receptor cause a group of rare disorders characterised 
by severe insulin resistance like type A insulin resistance and Lipodystrophy 
syndromes [4]. 
Diseases of the exocrine pancreas 
DM secondary to pancreatic disease is commonly referred to as pancreatogenic 
diabetes or type 3c DM. The prevalence of this kind of diabetes is 5% to 10% 
among all diabetic subjects. In nearly 80% of all type 3c diabetes mellitus 
cases, chronic pancreatitis seem to be the underlying disease [7]. The other 
common causes are cystic fibrosis and hereditary hemochromatosis. 
Endocrinopathies 
Several hormones, such as adrenaline, glucagon, cortisol and growth hormone 
antagonise the actions of insulin.  Endocrine abnormalities involving primary 
over-secretion of these hormones can result in overt diabetes including 
Cushing‟s syndrome, due to pituitary or adrenal disease or to exogenous 
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glucocorticoid administration, acromegaly, catecholamine excess in 
pheochromocytoma and glucagon secreting tumours (Glucagonomas) [4]. 
Drug or chemical induced diabetes mellitus 
A large number of drugs can impair glucose tolerance by decreasing insulin 
secretion, increasing hepatic glucose production or causing resistance to the 
action of insulin. The common drugs implicated are glucocorticoids, oral 
contraceptives, beta blockers, thiazide diuretics, nicotinic acid, statins and drugs 
like tacrolimus, sirolimus and cyclosporine used to prevent transplant rejection 
[4]. 
Gestational diabetes 
Gestational diabetes mellitus (GDM) is traditionally defined as “Carbohydrate 
intolerance of varying severity with onset or first recognition in pregnancy” [8]. 
The new definition “diabetes first recognised in the second or third trimester of 
pregnancy that is not clearly overt diabetes” reflects the changes in the 
approach to this condition [9]. It is described in detail later. 
Latent autoimmune diabetes of the adult (LADA) 
Individuals diagnosed with autoimmune diabetes when they are adults and who 
may not initially require insulin treatment have been classified as having latent 
autoimmune diabetes of the adult (LADA). [10]. It is also called slowly 
progressive insulin-dependent diabetes or type 1.5 diabetes [10]. 
1.1.3  Epidemiology of diabetes mellitus 
The prevalence of DM has significantly increased in the last 20 years from 30 
million cases in 1985 to 382 million in 2013 [4]. The Centre for Disease Control 
and Prevention (CDC) in its most recent estimate for the US (2012) estimated 
that 9.3% of the population had diabetes and 28% of the individuals with 
diabetes were undiagnosed [4]. 
The prevalence as well as the type of DM also varies in the different regions of 
the world due to ethnic, genetic and environmental influences. Scandinavia has 
the highest incidence of T1DM, and the lowest is in the Pacific Rim. Northern 
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Europe and the US have an intermediate incidence [4]. The prevalence of 
T2DM is highest in certain Pacific Islands and in the Middle East, and low in 
Russia and China [4]. In the United States, DM was listed as the seventh 
leading cause of death [4]. 
1.1.4  Pathophysiology of DM 
Regulation of glucose homeostasis 
Glucose homeostasis is maintained by a balance between hepatic glucose 
production and peripheral glucose uptake and utilisation. Insulin is initially 
synthesised as preproinsulin in the β cells of the pancreatic islets. Subsequent 
proteolytic processing removes the peptide giving rise to proinsulin [4]. 
Cleavage of an internal fragment from proinsulin generates the C peptide and 
the A (21 amino acids) and B (30 amino acids) chains of insulin, which are 
connected by disulphide bonds. The mature insulin molecule and C peptide are 
stored together and co-secreted from secretory granules in the β cells. C-
peptide is cleared more slowly than insulin and is therefore a useful marker of 
insulin secretion [4]. 
Insulin secretion 
Glucose is the key regulator on insulin secretion by the pancreatic β cell. 
Glucose levels greater than 3.9 mmol/L stimulate insulin release, primarily by 
enhancing protein translation and processing. It begins with the transport of 
glucose into the β cell. Glucose phosphorylation by glucokinase is the rate 
limiting step [4]. Further metabolism of glucose-6-phosphate via glycolysis 
generates ATP, which inhibits the activity of an ATP-sensitive K channel. 
Inhibition of the K channel induces β cell membrane depolarisation, which 
opens calcium channels and stimulates insulin secretion [4].  
Insulin action 
After insulin is secreted into the portal venous system, 50% is removed and 
degraded by the liver. Unmetabolised insulin enters the systemic circulation 
where it binds to receptors in target sites. The molecular signal initiating insulin 
action in humans involves activation of the insulin receptor tyrosine kinase, 
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resulting in phosphorylation of insulin receptor substrates (IRSs) on multiple 
tyrosine residues. These phosphotyrosine residues act as docking sites for 
proteins, including the p85 subunit of phosphoinositide 3‟ kinase (PI3K).  
Binding of the p110 subunit of PI3K to p85 activates the lipid kinase that 
promotes glucose transport [11]. The signals downstream of PI3K are unknown.  
Pathogenesis of type 1 diabetes mellitus 
It is believed that T1DM develops as a result of the additive effects of genetics, 
environmental and immunological factors ultimately causing destruction of 
pancreatic β cells and insulin deficiency [4]. These patients may either progress 
rapidly to clinical diabetes or evolve slowly. DM manifests when 70-80% of β 
cells are destroyed. The transition to frank diabetes may be seen during 
puberty, pregnancy or during infections which are associated with increased 
insulin requirements [4]. It is now known that most individuals with T1DM have 
the HLADR3 and/or DR4 haplotype. T1DM has a genetic predilection with a 15-
fold increased risk among family members [5].  
Pancreatic antibodies are characteristic of T1DM. Five autoantibodies have 
been detected- Glutamic acid decarboxylase (GADA) antibodies, islet cell 
antibodies (ICA), insulin autoantibodies (IAA), protein tyrosine phosphatase 
antibodies (ICA512 or IA2A) and zinc transporter protein (ZnT8). Highly sensitive 
laboratory measurements can capture 98% of the individuals with auto 
antibodies at diagnosis. However, commercial laboratories do not have 
relatively sensitive or specific assays that measure all 5 auto antibodies. 
Therefore, it is inappropriate to report a patient as autoantibody negative. Also, 
testing far out from diagnosis may be a cause of “false negative” results as 
antibody titres diminish in time [5].  
After the initial clinical presentation of T1DM, a “honeymoon” phase may ensue 
during which time glycaemic control may be achieved with small doses of 
insulin or, rarely insulin is not needed. Eventually, this fleeting phase of 
endogenous insulin production from residual beta cells disappears [4].  
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Pathogenesis of type 2 diabetes mellitus 
T2DM has also been suggested to have a genetic component and there is an 
increased risk of DM in an individual if one of his parents has the disease; if 
both parents have the disease, the risk approaches 40%. The aetiology of 
T2DM is multifactorial and is contributed by genetic factors as well as lifestyle 
factors like obesity and decreased physical activity [4]. The pathophysiology of 
T2DM involves a varying combination of impaired insulin secretion, insulin 
resistance, excessive hepatic glucose production and abnormal lipids. Obesity, 
specially visceral obesity is seen in 80% or more of the patients with T2DM [4]. 
In patients with T2DM, insulin resistance develops years before they present 
with the diagnosis. This result in the liver, skeletal muscle and adipocytes all  
becoming less sensitive to the action of insulin resulting in a fasting and 
postprandial hyperinsulinemia. This compensates and counters the insulin 
resistance for some time. However, with time, the β cell fails to maintain the 
high rate of insulin secretion and the relative insulinopenia, relative to the 
degree of insulin resistance leads to the development of impaired glucose 
tolerance and ultimately overt diabetes mellitus.  
Chronic hyperglycaemia can paradoxically impair islet function and this is 
known as “glucose toxicity” and leads to worsening of hyperglycaemia. In 
addition, elevation of free fatty acids known as “lipotoxicity” and dietary fat can 
also worsen islet function. Reduced GLP-1 action can also contribute to 
reduced insulin action [4].  
Insulin resistance in T2DM involves both the liver and peripheral muscle 
tissues. Thus, hepatic glucose production fails to suppress normally and muscle 
uptake is diminished. The accelerated rate of hepatic glucose output is entirely 
due to augmented gluconeogenesis [11]. There is evidence that the loss of the 
first phase of insulin secretion is the earliest detectable abnormality in patients 
destined to develop DM. Defects at the level of the β cell, muscle or the liver 
can lead to the development of glucose intolerance. The full blown syndrome of 
T2DM requires the simultaneous presence of two major defects, insulin 
resistance and impaired β function [11].  
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Obesity, which commonly accompanies T2DM, particularly in a central or 
visceral location is thought to be part of the pathologic process. The increased 
adipocyte mass leads to increased levels of circulating free fatty acids and 
adipokines like tumour necrosis factor α (TNF α), leptin, resistin and 
adiponectin. In addition to regulating body weight, appetite and energy 
expenditure, adipokines also modulate insulin sensitivity. Increased production 
of adipokines may cause insulin resistance in skeletal muscle and liver [4]. 
Insulin resistance in adipose tissue causes increased lipolysis and free fatty 
acids flux from adipocytes leading to increased lipid synthesis in hepatocytes. 
Very low density lipoproteins (VLDL) and triglycerides are mainly synthesised. 
This leads to lipid storage or steatosis in the liver and may lead to non-alcoholic 
fatty liver disease and abnormal liver function tests. This is also responsible for 
the dyslipidaemia characterised by elevated triglycerides, low high density 
lipoprotein (HDL) levels and high low density lipoprotein (LDL) levels seen in 
T2DM.  
1.1.5  Clinical presentation 
Type 1 diabetes mellitus 
In T1DM, the classical clinical presentation is polyuria, polydipsia and severe 
weight loss due to increased catabolism and hyperglycaemia [1]. Diuresis is 
caused mainly by the osmotic effect of glucose causing polyuria, nocturia and 
enuresis in children. Excessive thirst can occur and can be precipitated by 
sugary drinks. Severe weight loss occurs due to the loss of fat and muscle and 
dehydration. These may be accompanied by systemic symptoms like tiredness 
and lack of energy and blurred vision due to changes in the shape of the lens 
due to osmotic shifts [1]. Sometimes, they present with diabetic ketoacidosis 
with vomiting, acidotic breathing and altered consciousness and may progress 
to coma [1].  
Type 2 diabetes mellitus 
The common presenting features of T2DM are polyuria, polydipsia, blurred 
vision due to hyperglycaemia related refractive changes in the lens, infections 
like genital candidiasis and weight loss. Sometimes, patients may present in the 
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hyperosmolar non-ketotic state with confusion or coma, but they rarely have   
ketoacidosis. Sometimes, patients present with the complications of diabetes at 
the time of diagnosis of T2DM [1]. 
Chronic complications can be divided into vascular and nonvascular 
complications [1]. The vascular complications are further divided into 
microvascular comprising of retinopathy, neuropathy, and nephropathy and 
macrovascular complications including coronary heart disease, peripheral 
arterial disease, and cerebrovascular disease. Nonvascular complications 
include infections and dermopathy. Gastroparesis could be considered a 
microvascular complication with autonomic neuropathy [4]. 
1.1.6  Diagnosis 
The international committee of experts comprising of members appointed by the 
American Diabetes Association (ADA), the European Association for the Study 
of Diabetes (EASD) and the International Diabetes Federation (IDF) has issued 
diagnostic criteria for DM based on the two premises that the level of glycaemia 
leading to complications is more important than a deviation from a population 
based mean and the response to an oral glucose tolerance test (OGTT) differs 
among individuals [4]. 
The criteria for diagnosis of DM are symptoms of DM plus random blood 
glucose concentration > 11.1 mmol/L (200mg/dl) or fasting plasma glucose 
(FPG) > 7mmol/L (126mg/dl) or (glycated haemoglobin) HbA1c > 6.5% or 2-hour 
plasma glucose value > 11.1 mmol/L (200mg/dl) during an OGTT [4]. Impaired 
Fasting Glucose (IFG) is defined as FPG of 5.6-6.9 mmol/L (100-125mg/dl).  
World Health Organisation (WHO) defines IFG as FPG of 6.1-6.9 mmol/L (110-
125mg/dl). Plasma glucose levels between 7.8 and 11 mmol/L (140 and 199 
mg/dl) following an oral glucose challenge, is termed as Impaired Glucose 
Tolerance (IGT) [4]. It is also known as “pre-diabetes”, “increased risk of 
diabetes” (ADA) or intermediate hyperglycaemia (WHO) [4]. 
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1.1.7  Principles of management 
The goals of therapy in T1DM and T2DM are to reduce symptoms of 
hyperglycaemia, and decrease the long term microvascular and macrovascular 
complications of DM while allowing the patient to achieve as normal a lifestyle 
as possible [4]. 
The care of an individual with DM requires a multidisciplinary team including 
primary care provider and preferably a diabetologist, a diabetes educator and a 
nutritionist with the patients‟ participation and input at the centre of the care. In 
addition, experienced subspecialists including neurologists, nephrologists, 
vascular surgeons, cardiologists, ophthalmologists, urologists and podiatrists 
would be needed as required [4]. It is equally important to have a holistic view 
towards the management of DM and tackle other cardiovascular risk factors like 
hypertension, dyslipidaemia, obesity and smoking along with the 
hyperglycaemia. This would have a positive impact on the timing of onset and 
severity of the macrovascular complications. About 80% of patients with T2DM 
are obese as are at least 30% of those with T1DM. Obesity increases insulin 
resistance, dyslipidaemia and worsens hypertension, besides being an 
independent risk factor for heart disease. Therefore weight reduction should be 
given utmost importance in treating obese patients with DM [1]. 
In T2DM, when dietary therapy fails to achieve euglycaemia, glucose lowering 
oral agents like sulphonylureas, biguanides, and thiazolidinediones or insulin, 
either singly or in combination, is added. Newer anti-hyperglycaemic agents like 
Glucagon-like peptide-1 (GLP-1) receptor agonists and Sodium-glucose Co-
transporter-2 (SGLT2) Inhibitors are also available for the treatment of T2DM. 
Insulin is the cornerstone for the treatment of T1DM and is usually given as the 
basal bolus regimen.  
Biguanides 
Historically, biguanides can be traced from the use of galega plant (Galega 
officinalis) also known as “Professor Weed” or “French lilac” for treating DM in 
medieval Europe. Biguanides are synthesised from guanidine, the active 
component of galega plant. The incidence of lactic acidosis with metformin in 
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therapeutic doses is rare [12]. Recently, a study was designed to determine 
whether the use of metformin in type 2 diabetic patients with various levels of 
renal insufficiency is associated with an increased risk of lactic acidosis [13]. 
The authors concluded that the overall incidence for lactic acidosis for patients 
on metformin in the study was within the range of rates reported in the literature 
for patients with T2DM, and no significant difference was observed in patients 
with normal, mildly reduced, moderately reduced or severely reduced renal 
function [13]. 
Metformin is a dimethylbiguanide that is freely soluble in water and does not 
undergo substantial metabolism. The clinical efficacy of metformin requires the 
presence of insulin and involves several therapeutic effects, some of which are 
mediated via increased insulin action and some are not directly insulin 
dependent [14]. Metformin‟s principal mode of action is suggested to be on the 
liver. Metformin suppresses hepatic gluconeogenesis by potentiating the effect 
of insulin, reducing the hepatic extraction of lactate and by opposing the effect 
of glucagon. Also, metformin reduces the rate of glycogenolysis and decreases 
the activity of hepatic glucose-6-phosphatase [14]. 
Metformin also enhances insulin stimulated glucose uptake in the skeletal 
muscle by increased movement of glucose transporters into the cell membrane. 
This is associated with increased glycogen synthetase activity and glycogen 
storage [14]. Metformin also causes an insulin- independent suppression of fatty 
acid oxidation and a reduction in hypertriglyceridemia, thus reducing the energy 
supply for gluconeogenesis. This is associated with decreased synthesis and 
increased clearance of VLDL. Reduction in triglyceride levels reduces insulin 
resistance [14]. 
Molecular action of metformin 
Metformin has effects on the cell membrane and especially on the mitochondrial 
membranes [15]. The physiological function of the plasma membrane depends 
on the ability of its protein components to freely move in the phospholipid 
bilayer. In clinical and experimental diabetes, there is reduction in the 
membrane fluidity or increased membrane stiffness or viscosity. Metformin has 
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been shown to increase the fluidity of human plasma membrane [15]. Metformin 
was also associated with an 80% increase in the activity of AMP-activated 
protein kinase (AMP-kinase). The enzyme AMP-kinase is involved in multiple 
aspects of glycaemic regulation, including the regulation of GLUT4 glucose 
transporters and fatty acid oxidation [14]. More recently, metformin is also 
thought to be responsible for a reduction in the lactate and glycerol metabolism 
to glucose. Metformin exerts its anti-hyperglycaemic effect through inhibition of 
Complex 1 of the mitochondrial respiratory chain [15]. 
Several mechanisms have been suggested for a gut effect of metformin 
including delayed intestinal glucose absorption, augmented lactate production 
by enterocytes, and enhanced secretion of gastrointestinal hormones containing 
glucagon-like-peptide 1, bile acid metabolism and potential role of intestinal 
microbiota. Recently, one study has offered clinical evidence suggesting the 
primary effect of metformin resides in the human gut [16].  
Long term hyperglycaemia leads to glycation of proteins within the vascular 
wall. The non-enzymatic reaction between sugars, such as glucose, and free 
amino groups of proteins is also called the Maillard reaction, glycation or 
glycoxidation. The Maillard reaction ultimately results in increased production of 
highly chemically reactive glucose and alpha-dicarbonyl compounds which lead 
to the production of a large number of complex chemically irreversible 
structures called advanced glycation end products (AGE).  The accumulation of 
AGE within the vascular system may impair the structure and function of 
cardiovascular tissues and lead to the cardiovascular complications of diabetes. 
AGE promotes inflammation and oxidative stress. This may stimulate release of 
growth factors, cytokines and reactive oxygen species that are pro- atherogenic 
[17]. Metformin has been suggested to reduce the production of AGE indirectly, 
through reduction of hyperglycaemia and directly, via an insulin dependent 
mechanism. The chemical formation of AGE depends on the production of 
intermediates like glycoxal or methyl glyoxal. Metformin may act by 
detoxification of methylglycoxal to form Trizepinone and be cardioprotective 
[17]. 
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1.2  Gestational diabetes 
1.2.1 Introduction 
DM in pregnancy may be pre-gestational, which is when a woman with 
established DM becomes pregnant, or gestational.  
The International Association of Diabetes and Pregnancy Study Groups 
(IADPSG), the ADA and others have recently attempted to distinguish women 
with probable pre-existing DM that is first recognised during pregnancy (overt 
diabetes) from transient manifestation of pregnancy related insulin resistance 
(gestational diabetes) [18].  
The prevalence of gestational diabetes (GDM)  is increasing worldwide as 
pregnant population is becoming older and also as the prevalence of obesity is 
increasing [19][20]. Using the new IADPSG criteria proposed in 2010, the global 
prevalence of hyperglycaemia in pregnancy has been estimated at 17%, with 
regional estimates varying between 10% in North America and 25% in 
southeast Asia [21]. 
1.2.2  Pathogenesis 
Glucose metabolism during normal pregnancy 
Carbohydrate metabolism towards the second half of pregnancy is directed 
towards supplying glucose and amino acids to the growing fetus while providing 
extra free fatty acids, ketones and glycerol as maternal fuel. Normal pregnancy 
is characterised by hyperplasia of the insulin-secreting pancreatic β cells, 
increased insulin secretion and an early increase in insulin sensitivity followed 
by progressive insulin resistance. The lactogenic hormones prolactin and 
human placental lactogen (HPL) cause an increase in the number of pancreatic 
β cells in pregnancy, through unclear mechanisms [22]. 
Maternal insulin resistance in normal pregnancy begins in the second trimester 
and peaks in the third trimester. Several hormones that are elevated in the 
maternal circulation during pregnancy like progesterone, HPL, cortisol and 
prolactin are responsible for causing insulin resistance [1]. Progesterone 
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prohibits normal changes of the pancreatic β cell reserve during pregnancy and 
is hugely responsible for increased insulin resistance [1]. HPL causes a 
decrease in phosphorylation at insulin receptor substrate 1 and insulin 
resistance increases as the level of HPL rises in the second trimester [1]. HPL 
peaks at 30 weeks of gestation and plays a major role in maternal insulin 
resistance [23]. Additionally, cortisol and prolactin have an effect on insulin 
function and are also instrumental in increasing insulin resistance [1]. The 
serum leptin levels are significantly higher and the adiponectin levels lower in 
women with GDM compared to women without GDM and these may be 
contributory factors in altering carbohydrate-fat metabolism leading to 
development of GDM [1]. 
Pathogenesis of GDM 
Studies using the hyperglycaemic-euglycaemic glucose clamp technique and 
intravenous-glucose-tolerance-test have indicated that insulin action in late 
normal pregnancy is 50-70% lower than in nonpregnant women. Metabolic 
adaptations do not fully compensate in GDM leading to glucose intolerance. 
GDM may reflect a predisposition to T2DM or may be an extreme manifestation 
of metabolic alterations that normally occur in pregnancy [22]. 
Buchanan et al studied insulin sensitivity in the third trimester and reported that, 
mild gestational diabetes is characterised by an impairment of β cell function 
rather than an exaggeration of the normal insulin resistance of late pregnancy 
[24].  
  
1.2.3 Screening 
GDM is usually diagnosed by an OGTT which is used as a screening test [18]. 
Sometimes, GDM is suspected when the scan shows a macrosomic baby or 
polyhydramnios or mother presents with significant and persistent glycosuria.  
A systematic review was performed by the United States Preventive Services 
Task Force (USPSTF) on the accuracy of screening tests for GDM, the benefits 
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and harms of screening before and after 24 weeks of gestation, and the benefits 
and harms of treatment. They found good evidence to support universal 
screening after 24 weeks but not for universal screening earlier in pregnancy 
[25]. 
There is also no consensus regarding the diagnostic test criteria for gestational 
diabetes. O‟Sullivan and Mahan formulated the diagnostic criteria depending on 
the future risk of T2DM in the mother and it was not necessarily to identify 
pregnancies with increased risk for adverse perinatal outcomes [8].  In the UK, 
most NHS hospitals used the WHO 1999 diagnostic criteria for the diagnosis of 
GDM, wherein an oral glucose tolerance test result of fasting plasma glucose of 
≥ 6 mmol/l or a 2-hour plasma glucose level ≥ 7.8 mmol/l is considered 
diagnostic of GDM [26].These have been replaced in February 2015 by the 
criteria suggested by National Institute of Health and Care Excellence (NICE) 
guidance, wherein a diagnosis of GDM is made on the basis of fasting plasma 
glucose level ≥ 5.6 mmol/litre or a 2-hour plasma glucose level ≥ 7.8 mmol/litre 
[27].   
The Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study has 
demonstrated a linear correlation between fasting glucose levels and post 75 g 
oral glucose tolerance test levels to maternal, perinatal and neonatal outcomes. 
These adverse outcomes were also seen at below the current accepted level. 
There appeared to be no apparent threshold. This would suggest that GDM and 
fetal macrosomia could be considered a metabolic complication of diabetes like 
macrovascular disease rather than a microvascular complication of diabetes. 
Macrovascular disease with its multiple metabolic predictors does not have a 
sharp cut off. 
The IADSPG have now suggested new criteria for the screening of GDM on the 
basis of findings from the HAPO study [28]. A fasting glucose > 5.1mmol/l, 1-
hour post OGTT value > 10 mmol/l or a 2-hour value > 8.5 mmol/l were 
considered abnormal. Only 1 abnormal value would be sufficient to make the 
diagnosis of GDM in the women [28]. A study was undertaken to determine 
whether adopting the IADPSG criteria would be cost-effective, compared with 
 15 
the current standard of care. It concluded that the IADPSG recommendation for 
glucose screening in pregnancy is cost-effective [29] 
1.2.4 Implications for mother and fetus 
The complications of DM in pregnancy are mainly due to maternal 
hyperglycaemia resulting in fetal hyperinsulinemia [1]. According to the modified 
Pedersen hypothesis, fetal hyperinsulinemia may lead to chronic fetal hypoxia, 
stimulating extramedullary haematopoiesis, fetal polycythaemia and neonatal 
hyperbilirubinemia leading to increased admission to neonatal intensive care 
units [4]. As insulin is an anabolic hormone, the macrosomic baby is fat and 
plethoric with enlarged organs especially the liver, and a disproportionately 
increased abdominal circumference. Other adverse outcomes could be 
preeclampsia and hydramnios. Macrosomia can lead to birth trauma and 
maternal morbidity from operative delivery [30]. Risk of macrosomia is great, 
when GDM is not recognised or is treated casually. Infants with macrosomia are 
at risk of shoulder dystocia, which can result in an increased risk for fracture of 
the clavicle and, more seriously, brachial plexus palsy during delivery [25]. 
Infants of women with GDM can potentially have other neonatal morbidities like 
hypoglycaemia, hypocalcaemia and poor feeding. GDM with onset in mid-
pregnancy or later pregnancy is not associated with an increased prevalence of 
congenital malformations. However, GDM diagnosed in early pregnancy with 
elevated fasting plasma glucose >6.7 mmol/l or HbA1c ≥ 7%, possibly 
represents pre-existing type 2 diabetes and is associated with a higher rate of 
congenital anomalies than found in the general obstetric population [30]. 
Macrosomia also possibly increases the risk of glucose intolerance and obesity 
in the offspring [30]. Identification and intensive management of GDM are 
associated with a decrease in neonatal morbidity and mortality and also a 
decrease in the likelihood of intrauterine deaths [30]. 
1.2.5 Management of gestational diabetes 
A multidisciplinary team involving obstetricians, physicians, specialist dietitian, 
nurses and midwives experienced in the care of pregnant women with diabetes 
is essential in the management of these patients. 
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The benefit of treatment of GDM is clearer from recent landmark studies. The 
results of the Australian Carbohydrate Intolerance in Pregnancy Study (ACHOIS 
Study) showed that there were significantly fewer complications in the infants of 
mothers in the intervention group (n=490) as compared to the infants of 
mothers receiving routine care (n=510). They concluded that perinatal mortality 
can be reduced by treating GDM and it also improves women‟s quality of life 
[31].  
Langer et al. studied 555 pregnant women with GDM diagnosed after 37 weeks 
in comparison with 1110 pregnant women treated for GDM and 1110 matched 
non diabetic pregnant women [32]. They concluded that lifestyle and dietary 
modifications and, when indicated, insulin therapy clearly improves outcome in 
GDM [32].  
A systematic review and meta-analysis of randomised trials in 2013 for the 
USPSTF found that appropriate management of GDM with nutritional therapy, 
self-blood glucose monitoring and administration of insulin, if target blood 
glucose concentrations are not met with diet alone resulted in reductions in 
preeclampsia, birth weight > 4000 g and shoulder dystocia [33]. 
In the Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study, 
obesity and GDM (diagnosed by IADPSG criteria) were independently 
predictive of fetal macrosomia, preeclampsia, primary Caesarean delivery and 
neonatal adiposity [34]. Macrosomia was more likely when GDM was present in 
the absence of obesity (Odds Ratio (OR) 2.2, 95% CI 1.9 to 2.5) than when 
obesity was present in the absence of GDM (OR 1.7, 95% CI 1.5 to 2.0) and the 
independent effects of GDM and obesity were additive. The odds ratio for birth 
weight > 90th percentile when both GDM and obesity was present was 3.6 (3.0-
4.3). Odds for birth weight >90th percentile were  progressively greater with both 
higher OGTT glucose and higher maternal BMI  [34]. 
Nutritional therapy for gestational diabetes 
The cornerstone of therapy for diabetes in pregnancy is diet [1]. Women are 
advised to reduce the proportion of carbohydrates to 35%-40% of the meals 
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and preferably use low glycaemic index carbohydrates which result in a slower 
and more even release of glucose [1]. The ADA recommends that nutrition 
therapy for GDM provide adequate nutrition to promote fetal and maternal 
health, achieve glycaemia with absence of ketones and provide adequate 
energy levels for appropriate weight gain in pregnancy [35].  
A recent meta-analysis showed that an overall low glycaemic index diet in which 
carbohydrate are mainly sourced from fruits, vegetables and whole grains, with 
low consumption of flour based products and potatoes had a favourable effect 
on blood glucose and lowered the need for insulin therapy [36]. 
Exercise 
The ADA encourages a program of moderate exercise as part of the treatment 
plan for women with GDM if no medical or obstetric contraindications to this 
level of physical activity [37].  
Glucose monitoring and targets 
The ADA recommends that women with GDM be asked to measure their blood 
glucose concentrations at least 4 times daily, pre-breakfast and one or two 
hours after the first bite of each meal.  This multiple testing allows recognition of 
women who should begin an anti-hyperglycaemic agent. Results are recorded 
in a log book along with dietary information [38]. The ADA and the American 
College of Gynaecologists (ACOG) currently recommend the following upper 
limits for glucose levels, with insulin therapy initiated if they are exceeded-   
Fasting glucose ≥ 5.3 mmol/l, 1-hour postprandial blood glucose ≥ 7.8 mmol/l, 
2-hour postprandial glucose ≥ 6.7 mmol/l. 
HbA1C may be a helpful test in assessing glycaemic control but has been 
suggested to be unreliable in pregnancy.  
Pharmacological therapy of GDM 
Conventionally, women with gestational diabetes were treated with insulin when 
diet alone failed to achieve euglycaemia.  
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Insulin Therapy 
Use of insulin preparations of low antigenicity may minimise the transplacental 
transport of insulin antibodies and hence human insulin which is the least 
immunogenic preparation is used [30]. The type of insulin used depends on the 
blood glucose profile of the patient. The newer insulin analogues, Lispro and 
Aspart have been investigated in pregnancy and shown to have acceptable 
safety profiles, minimal transfer across the placenta and no evidence of 
teratogenesis [30]. They both improve postprandial excursions compared to 
human regular insulin and are associated with lower risk of delayed 
postprandial hypoglycaemia. Insulin detemir is the only basal insulin analogue 
approved in pregnancy, Food & Drug Administration (FDA) category B 
classification [39]. 
Metformin 
Metformin is now gaining more acceptance as a safe, effective and a rational 
oral option offering advantages over insulin [40]. Metformin is a biguanide, 
which reduces insulin resistance and hepatic gluconeogenesis and stimulates 
GLP-1 release [41]. Metformin crosses the placenta but no teratogenic effects 
have been reported so far [42].  
The Metformin in Gestational Diabetes (MiG) trial concluded that in women with 
GDM, metformin alone or with supplemental insulin is not associated with 
increased perinatal morbidity as compared to insulin treatment and when 
women were asked what they would choose in next pregnancy, metformin was 
the preferred choice to insulin [40]. 
When the MiG investigators published their interim favourable safety data on 
metformin use in pregnancy, I, as part of the St Helier diabetes team, conducted 
a case control study in 2007 comparing the maternal and neonatal outcomes in 
women with GDM treated with either metformin or insulin [43]. In this previously 
published work, I concluded that the pregnancy outcomes in the 100 GDM 
women treated exclusively with metformin were comparable to a retrospective 
cohort of 100 insulin-treated GDM women attending the same clinic and 
managed by the same team. Women gained less weight from time of enrolment 
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to delivery in the metformin treated group as compared to the insulin group. I 
concluded that metformin, being an oral medication was more acceptable to 
patients, was less expensive and was also more cost effective as compared to 
insulin. In 2012, I, along with the St Helier diabetes team conducted another 
case-control study on pregnancy outcomes in women treated with metformin for 
GDM [44]. I compared the pregnancy outcomes in 324 metformin treated GDM 
women with 175 GDM women treated with diet alone and matched for age and 
ethnicity. In this second study, I  again concluded that metformin treatment had 
a favourable impact on reducing the rates of Large for Gestational Age (LGA) 
babies despite more severe glucose intolerance at baseline [44]  
Metformin therapy has some advantages and disadvantages compared with 
insulin therapy. A recent systematic review and meta-analysis in 2015, 
comparing different treatments for GDM showed that compared with insulin, use 
of metformin resulted in less gestational weight gain (mean difference = -1.1kg, 
95% Confidence Interval (CI) -2.2 to -0.06kg) but lower gestational age at 
delivery and a higher risk of preterm birth [39]. There was no statistical 
difference between metformin and insulin users in mean birth weight or risk of 
macrosomia, but a trend towards a lower rate of any neonatal hypoglycaemia 
was noted in metformin users  [39]. 
1.3  Obesity 
1.3.1  Prevalence of obesity 
The World Health Organisation (WHO) defines obesity as abnormal or 
excessive fat accumulation that may impair health [45]. Body mass index (BMI) 
is the measurement of the mass in the human body, in kilograms, divided by the 
height in meters squared (Equation 1-1). 
Equation 1-1: Body mass index (BMI) 
 
 
BMI =  Weight (kg) 
           Height2 (m2) 
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BMI is used as a rough estimate of obesity - a BMI > 25 kg/m2 is called as 
overweight and a BMI ≥ 30 kg/m2 is categorised as obesity. Obesity is further 
subdivided into class I (BMI 30-34.9 kg/m2, Class II (BMI 35-39.9 kg/m2) and 
class III (BMI ≥ 40 kg/m2) [45]. The BMI may not provide an accurate measure 
of obesity but it provides a very useful population level measure of overweight 
and obesity and there is no variation between sexes and at all ages in adults. 
However, it does not always correspond to the same degree of fat content in 
different individuals as the contribution of lean mass to body weight may differ in 
people [45]. 
The prevalence of obesity, worldwide, has more than doubled since 1980. In 
2014, 39% of adults aged 18 years and more were overweight. Overall, about 
13% of the world‟s adult population (11% of men and 15% of women) were 
obese in 2014 [45]. 
Overweight and obesity are estimated to be the fifth leading risk for global 
deaths. Besides that, obesity is also responsible for up to 44% of the diabetes 
burden, 23% of the heart disease burden and a large chunk of certain cancer 
burden [45]. 
It has been estimated worldwide that the proportion of adults with BMI > 25 
kg/m2 has increased between 1980 and 2013 from 28.8% to 36.9% in men and 
from 29.8% to 38% in women [46]. Increases were observed in both developed 
and developing countries. The reported prevalence rates of obesity included 
20% of men and 21.7% of women in Belgium, 21% of men and women in the 
UK and 21% of men and 33% of women in Mexico [46]. 
1.3.2  Screening measures 
Measuring BMI is the first step to determine the degree of overweight. The BMI 
is easy to measure, reliable and correlated with percentage body fat and body 
fat mass. However, the disadvantages of BMI are that it may overestimate the 
degree of fatness in individuals who are overweight but very muscular like 
professional athletes or bodybuilders and underestimate in older persons 
because of loss of muscle mass associated with aging. 
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Also, the definition of overweight and obesity varies with race and population. In 
some populations, the level of risks in terms of per cent body fat is reached at a 
much lower BMI (South Asian) and in others a higher BMI (Blacks) as 
compared with Whites. A study comparing South Asian and European subjects 
showed that the mean BMI associated with the development of an adverse 
metabolic profile, defined by markers of glucose and lipid metabolism was 21 
kg/m2 in South Asians and 30 kg/m2in Europeans [47]. 
Waist Circumference 
In addition to BMI, waist circumference (WC) is a useful tool in overweight and 
obese adults to assess abdominal obesity. A WC of ≥ 40 inches (102 cm) for 
men and ≥ 35 inches (88 cm) for women is considered significantly elevated 
and indicative of increased cardiometabolic risk [48]. There is evidence that 
patients with abdominal obesity (also called central adiposity, visceral, android, 
or male-type obesity) are at increased risk for heart disease, DM, hypertension, 
dyslipidaemia, and non-alcoholic fatty liver disease [49]. It has been found that 
there is ethnic variability in WC values that predict increased risk. As an 
example, it has been observed that Japanese-Americans and Indians from 
South Asia have more total fat and visceral fat and therefore may be at higher 
risk of developing T2DM for a given BMI than whites [50]. Consequently, in 
Asian females a WC > 80 cm and in Asian males a value > 90 cm are 
considered abnormal [50]. 
Data from the Third National Health and Nutrition Examination Survey 
(NHANES III) study suggest that normal-weight central obesity is associated 
with higher mortality than BMI-defined obesity, especially in individuals without 
central obesity [51]. A survey of over 15,000 individuals, men with a normal BMI 
but central obesity (Waist Hip Ratio (WHR) ≥ 0.9) had the highest total mortality 
risk when compared to men without central obesity who were normal weight, 
overweight or obese (HR 1.9, 2.2, and 2.4, respectively). Similarly, normal 
weight women with central obesity (WHR ≥ 0.85) had higher mortality risk 
compared to normal weight and obese women without central obesity (HR 1.5 
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and 1.3, respectively). A limitation of the study is that no quantitative imaging 
studies of adipose tissue were performed [51].  
Body Composition Analysis  
Body composition can be analysed by measuring body impedance using 
instruments such as Inbody 720R. This instrument performs body composition 
analysis using Direct Segmental Multi-Frequency Bioelectrical Impedance 
Analysis Method (DSM- BIA Method). The InBody 720 gives a quantitative 
value for the various body compartments which equals the weight of each 
compartment, when added together they equal the person‟s weight. It measures 
BMI, WHR and various body compartments like lean body mass, total 
percentage body fat (PBF) and visceral fat mass (VFM). The bioelectrical 
impedance analysis (BIA) method is based on the electric resistance difference 
between the fat and components of other organs [52]. 
Validation of InBody 720  
The InBody 720 has been validated and correlates well with intra-abdominal fat 
area assessed by CT scan [53] and DEXA [54]. Ogawa H et al. studied the 
efficacy of bioelectrical impedance analysis by InBody 720 as a new tool for 
measuring visceral fat area [53]. They concluded that visceral fat area values 
measured by InBody 720 significantly correlated with those by computed 
tomography (R = 0.8) [53]. Malavolti M et al. also compared Eight-polar 
bioelectrical impedance analysis (BIA) against dual-energy X-ray 
absorptiometry (DEXA) for the assessment of total and appendicular body 
composition in 110 healthy adults [54]. They concluded that Eight-polar BIA 
offers accurate estimates of total and appendicular body composition [54]. 
InBody 720 has also been used in studies of patients with obesity [55][56].  
A study at Osaka University was conducted to assess the correlation of  VFA 
(visceral fat area) by the BIA method with VFA determined by CT scan [52]. The 
usefulness of abdominal BIA on evaluating metabolic syndrome was also 
investigated. The best combination of sensitivity and specificity for detecting 
subjects with multiple risk factors was VFA ≥ 100 cm2. The VFA by BIA 
correlated significantly with VFA determined by CT (r=0.9, P<0.0001). They 
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concluded that BIA is a simple, non-invasive, non-expensive method for 
estimation of visceral fat with excellent correlation with CT measurements and 
should be used in routine clinical practice [52].  
It has been also been shown to be safe in the second and third trimesters of 
pregnancy and has also been validated against deuterium and 
hydrodensitometry techniques for body composition analysis [57][58]. Van Loan 
MD et al. examined the accuracy of bioelectrical impedance spectroscopy for 
estimating fluid volumes before, during and after pregnancy and concluded that 
bioimpedance may be useful in estimating volumes of extracellular fluid (ECF) 
and total body water (TBW) during pregnancy [57]  McCarthy et al compared 
various methods of determining maternal body composition in pregnancy 
published between 1950 and 2004  [58]. They conclude that bioimpedance is a 
safe technique and uses simple equipment [58]. DSM-BIA is also an accurate 
technique for assessing body water distribution which changes during 
pregnancy [59].  
1.3.3 Pathophysiology of obesity 
Metabolic and socioeconomic factors associated with obesity have been 
identified. Among the former are a low metabolic rate, increased carbohydrate 
oxidation, insulin resistance, and low sympathetic activity. Among the latter are 
lower socioeconomic class, lower education level, and cessation of smoking 
[60]. Genetic factors play a permissive role and interact with environmental 
factors to produce obesity [61].  
The fundamental problem in obesity is an imbalance of energy between calories 
consumed and calories expended. An increase in body fat requires that energy 
intake be increased persistently over energy expenditure. However, there is a 
feedback mechanism between energy intake and expenditure that tends to 
maintain body weight. Weight gain is associated with an increase in energy 
expenditure which retards further weight gain, whereas weight loss is 
associated with a decrease in total and resting energy expenditure, a change 
that makes further weight loss more difficult [62]. 
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The feedback control system consists of the cellular processes for energy 
expenditure and for digestion and utilization as fuels. The central nervous 
system controller in the hypothalamus receives afferent signals from the 
periphery about deficits or surpluses of foods. The controller then initiates 
metabolic and cognitive responses according to whether food is needed and 
also initiates signals that alter metabolism of nutrients and the cognitive 
processes for food seeking. 
The afferent signals are hormones like leptin. Gut hormones like glucagon-like 
peptide-1 (GLP-1), cholecystokinin, enterostatin, and polypeptide Y 3-36 reduce 
food intake. Ghrelin is produced in the stomach and duodenum, and has two 
major effects: it stimulates growth hormone secretion and increases food intake 
in humans. Serum concentrations of ghrelin increase in anticipation of a meal, 
and are suppressed by food ingestion [63]. 
Secondary causes of obesity though uncommon, should be considered and 
ruled out. The neuroendocrine causes of obesity are hypothalamic obesity, 
Cushing‟s syndrome, polycystic ovaries, hypogonadism, hypothyroidism, and 
psedohypoparathyroidism. Drugs like insulin, sulfonylureas, thiazolidinediones, 
antipsychotics, antidepressants and antiepileptics can cause weight gain [64]. 
 
 
Obesity and insulin resistance 
The association of obesity and T2DM is now well recognised and the link is 
through insulin resistance. The mechanisms by which obesity causes systemic 
insulin resistance are unknown, but are thought to act through the adipo-insulin 
axis [65]. Insulin resistance with hyperinsulinemia is characteristic of obesity 
and is present before the onset of hyperglycaemia. After the onset of obesity, 
the first demonstrable changes are impairment in glucose removal and 
increased insulin resistance, which result in hyperinsulinemia. The 
hyperinsulinemia in turn increases hepatic very-low-density triglyceride 
synthesis, plasminogen activator inhibitor-1 synthesis, sympathetic nervous 
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system activity, and sodium reabsorption. These changes contribute to 
hyperlipidaemia and hypertension in obese subjects [66]. 
Adipocytes as endocrine cells 
Adipocytes are energy storage depots for triglycerides releasing fuel as fatty 
acids and glycerol in time of fasting and starvation. An additional role of the 
adipocyte is of a secretory cell [65]. Adipocytes secrete numerous peptide 
hormones and cytokines including TNF-a; plasminogen-activator inhibitor-1, 
which helps maintain haemostasis, angiotensinogen which regulates vascular 
tone and leptin which plays a central role in regulating energy balance. Adipose 
tissue can also produce active steroid hormones, including oestrogen and 
cortisol. Through these secreted peptides, adipocytes can influence local 
adipocyte biology as well as systemic metabolism in diverse sites like the brain, 
liver, muscle, β cells, gonads, lymphoid organs and systemic vasculature [65]. 
TNF-α has many effects on adipocyte function including inhibiting lipogenesis 
and increasing lipolysis. TNF-α may be a mediator for insulin resistance. TNF-α 
signalling impairs insulin signalling and can reduce GLUT4 gene expression 
[65]. 
Leptin, the product of the ob gene may be another contributor to insulin 
resistance [65]. Leptin has profound effect on satiety, energy expenditure and 
neuroendocrine function. Leptin is viewed as being primarily involved in the 
starvation/feeding switch. The absence of leptin in both rodents and humans 
produces severe obesity which is cured by leptin. The paradox that absence or 
excess of adipose tissue causes insulin resistance highlights the complexity of 
the relation [65]. 
1.4 Obesity in pregnancy 
1.4.1 Prevalence of obesity in pregnancy 
Obesity is defined as pre-pregnancy BMI ≥ 30 kg/m2 .The Confidential Enquiry 
into Maternal and Child Health (CEMACH) in its 2003-2005 triennia report has 
highlighted obesity in pregnancy as a major risk to mother and baby [67]. 
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CEMACH found that approximately one-thirds of the women who died were 
obese and 30% of the mothers who had a stillbirth or a neonatal death were 
also obese [67]. 
Galtier-Dereure et al. studied the complications of obesity in pregnancy and the 
costs in management of these patients and estimated that there is almost a five-
fold increase in antenatal care costs in obese women as they spend an average 
of 4.8 more days in hospital [68].  Similarly, there is an increase in costs of 
neonatal care also as there is a 3.5 fold increase in admissions to intensive care 
unit in babies born to obese mothers [68].  
A national project by the Centre for Maternal and Child Enquiries (CMACE) on 
maternal obesity in the UK, 2010 highlighted the increasing prevalence of 
obesity and the important findings are given below [69]. The UK prevalence of 
women with a known BMI ≥ 35 in pregnancy is high at 4.9% = 38,478 
maternities each year. 20% of the babies were LGA (twice as high as expected 
in the general population). Obese women with diabetes were more likely to 
have a LGA baby (40% versus 17%). Neonatal unit admissions were higher and 
correlated directly with maternal BMI. Caesarean sections rate was higher at 
37% (versus 25% in general maternities) in England [69].  
Heslehurst et al studied the trends in maternal obesity incidence rates in the 
UK. They reported that the proportion of obese women at the start of pregnancy 
has increased significantly over 19 years (1989 to 2007) from 9.9% to 16%. 
Predictors of maternal obesity are associated with health inequalities, 
particularly socio-economic disadvantage [70]. 
Sebire et al studied maternal obesity and pregnancy outcomes in 287,213 
pregnancies in London. He reported that, compared to normal BMI, the 
following outcomes were more common in obese women: GDM (OR 3.6), PET 
(OR 2.1), LGA (2.36). Also, excessive weight gain in pregnancy is associated 
with an increased risk of complications [71]. 
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1.4.2 Risks of Obesity in Pregnancy 
The risks associated with obesity in pregnancy can be antepartum, intrapartum, 
postpartum and offspring risks [68]. The antepartum risks are pregnancy-
induced hypertension/preeclampsia, spontaneous miscarriages, gestational 
diabetes, and increased risks of venous thromboembolism and ultrasound 
difficulties in fetal assessment. The intrapartum risks are increased Caesarean 
sections, and failed Vaginal delivery after Caesarean (VBAC, perineal trauma, 
shoulder dystocia, risks associated with anaesthesia and surgical difficulties. 
The postpartum risks are increased rates of puerperal infection and 
haemorrhage, decreased rates of breastfeeding initiation or continuation, 
postnatal depression and thrombo-embolic disorders. The offspring risks are 
higher risk for having congenital anomalies, stillbirths and increased risk of 
childhood and adult obesity [68].  
A study by Sheiner et al. aimed to investigate the correlation between maternal 
obesity and incidence of Caesarean section (CS) while controlling for 
confounding effects of other variables associated with obesity like diabetes and 
hypertension [72]. They found higher rates (27.8%) of CS among obese women 
as compared to normal weight women (10.8%), (OR=3.2, 95% CI 2.9 to 3.5, 
P<0.001) and this association remained significant even after corrections for 
confounders [72]. Another study reported a 9.5 fold increased risk of wound 
infection after CS when obesity and diabetes were both present (95% CI, 4.5 to 
19.2, P<0.01) [73]. 
Adverse outcomes are usually thought to be due to the increased prevalence of 
diabetes in obese women. However, non-diabetic obese women are also at 
greater risk of adverse outcome. Hence, other pathways are likely to play a role 
[74]. It may be due to adipose tissue-related dysregulation of metabolic, 
vascular, and inflammatory pathways, affecting many organ systems. Insulin 
resistance and abnormalities in inflammatory pathways have been linked to 
development of preeclampsia [75]. 
The HAPO study also demonstrated that increasing maternal BMI contributes to 
fetal size independent of variations in glycaemic exposure [76]. In addition to 
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the strong relationship with birth weight > 90th percentile, maternal BMI was also 
strongly related to fetal adiposity and hyperinsulinemia even after adjustment for 
maternal glycaemia. This suggests the potential importance of other nutrients 
including triglycerides, free fatty acids and amino acids and potentially of total 
caloric intake [76].  
All these studies show that numerically, more macrosomic babies are born to 
obese mothers than mothers with GDM [74] [76]. Fetal macrosomia is an 
important adverse outcome as it can lead to birth injuries like shoulder dystocia, 
fracture of the clavicle and brachial plexus injury. 
A 2011 systematic review showed that the odds of having ≥ 1 miscarriage were 
increased for obese women (OR 1.3, 95% CI 1.18 to 1.46) and overweight 
women (OR 1.1, 95% CI 1.0 to 1.2), when compared with women with normal 
BMI  [77].  
There is evidence of an association between obesity and hypertensive 
disorders during pregnancy. A large systematic review of 13 cohort studies 
found that the risk of preeclampsia doubled with each 5 to 7 kg/m2 increase in 
pre pregnancy BMI [78]. 
The underlying mechanism suggested is that the pathophysiologic changes 
associated with obesity related cardiovascular risk such as insulin resistance, 
hyperlipidaemia and subclinical inflammation are also responsible for the 
preeclampsia [79]. A large study in 2014, aiming to validate clinical risk factors 
for preeclampsia, concluded that being overweight or obese was the most 
important risk factor for both preeclampsia and severe preeclampsia with an 
attributable risk per cent of 64.9% and 64.4%, respectively [80]. 
Pre pregnancy BMI and maternal weight gain are both determinants of infant 
birth weight and obesity increases the risk of delivering a LGA infant [81]. This 
relationship is independent of the increased prevalence of GDM in obese 
women.  
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Maternal obesity and long-term effects on the child 
It has been proposed that the transmission of obesity risk from mother to the 
child can be explained by the “Developmental origins of disease” hypothesis, 
which suggests that elements of heritability can be transmitted in a non 
Mendelian way from one generation to the next [82]. However, it remains 
unproven whether these associations represent an intrauterine influence, or 
more simply reflect shared familial, genetic or lifestyle characteristics.  
Recently, rodent models of diet induced obesity have reported that the offspring 
develop increased adiposity, insulin resistance and hypertension [83]. Rodent 
studies have also implicated a raised n-6:n-3 fatty acid ratio in premature 
adipocyte maturation and proliferation [84]. The mechanism whereby nutrient 
status in early life can permanently influence the metabolic phenotype of the 
offspring is likely to involve epigenetic modification of DNA and this may lead to 
permanent change in organ structure, cell number or metabolic function [85].  
A human cohort study recently suggested that precocious development of 
neonatal fat depots, or persistently altered adipocyte metabolism in response to 
fetal metabolic and hormonal profile, may also contribute to obesity in later life 
[86]. A study showed a 3.6-fold greater risk of metabolic syndrome among LGA 
offspring of mothers with GDM as compared to appropriate-for-gestational age 
children [87]. 
1.4.3 Gestational weight gain in obese women 
A large cohort study of 120,251 pregnant, obese women delivering full-term 
infants concluded that it is beneficial to limit weight gain during pregnancy in 
obese pregnant women [88].  
Gestational Weight Gain (GWG) occurs to support the function of growth and 
development of the fetus [89]. It is related to changes in maternal and placental 
metabolism. The placenta acts as an endocrine organ and a barrier and 
transporter of substances between the two circulations [89]. Hence, changes in 
the maternal metabolism can alter fetal growth rate and, conversely, placental 
function can also change maternal metabolism through alterations in insulin 
 30 
sensitivity [89]. The Institute of Medicine (IOM) has revised its guidelines for 
weight gain in pregnancy in 2009 and included specific pregnancy weight 
guidance for underweight, normal weight and overweight and obese women 
and adolescents and women carrying twins or higher order multiples [89].  
A retrospective cohort study of 142 consecutive pregnancies in 28 women of 
normal weight, 39 overweight women and 75 obese women with T2DM was 
carried out to evaluate fetal growth in relation to GWG in women with T2DM 
[90]. The authors concluded that the infant birth weight was almost 0.5 kg 
higher in women with T2DM and excessive GWG than in women with non-
excessive GWG [90]. 
Excessive GWG is primarily related to an excessive increase in maternal 
adiposity in the absence of pathological oedema. There are several biologic and 
genetic factors that affect fat metabolism in pregnancy. Increased progesterone 
levels are responsible for fat accumulation during the first and second 
trimesters, and for fat mobilization during the third trimester. Also, increased 
leptin levels during pregnancy correlate positively with body fat content and 
body mass index (BMI) and appear to play a direct role in GWG and postpartum 
weight retention [91].  
Factors like maternal weight and gestational weight gain have been shown to 
impart greater risk for neonatal outcomes like macrosomia and shoulder 
dystocia, particularly in women diagnosed with GDM at lower glucose 
thresholds [92]. The study by Black et al. showed that the prevalence of LGA 
infants was significantly higher for overweight and obese women without GDM 
compared with their normal weight counterparts. They concluded that 
interventions that focus on obesity and gestational weight gain, regardless of 
GDM status, have the potential to reach far more women at risk of having a 
LGA infant [92]. 
1.4.4 Management of Obesity in Pregnancy 
Dietary Approaches 
 31 
A Cochrane review concluded that it may be more harmful than beneficial to 
restrict protein and energy in obese and overweight women [93]. However, 
studies have shown that cutting down on calories to 1600-1800 kcal/day 
restricts excessive weight gain in pregnancy without risking ketosis in the fetus 
and may be beneficial [94].  
Physical Activity 
The ACOG guidelines advocate moderate exercise for 30 minutes or more on 
most days of the week in obese pregnant mothers unless there are obstetric 
complications [95]. Though these recommendations are not evidence based, 
they are widely used. A Cochrane review on physical activity in pregnancy 
concluded that the current available data were inconclusive regarding risks or 
benefits to the mother or infant [96]. 
Behavioural Intervention 
There have been several studies using behavioural intervention to limit weight 
gain in pregnancy in obese women. Claesson et al. used a „motivational‟ talk 
approach in early pregnancy which was followed by an aqua-aerobics class and 
then followed weekly by a midwife. In this programme, obese women in the 
intervention group gaining only 8.7 kg which was significantly less than weight 
gained by the control group (11.3kg). Increased frequency of contact with the 
health care professional could have been a contributory factor [97]. Asbee et al. 
offered a single contact with the dietitian at the initial visit and this also reduced 
the weight gain in the intervention group (13 kg) versus the control group 
(16.1kg) [98]. However, none of these above lifestyle interventions brought any 
change to birth weight or any other pregnancy outcome.   
As in nonpregnant individuals, exercise with or without a healthy diet helps to 
prevent excessive weight gain and should be recommended, unless there are 
contraindications to exercise [99]. Several systematic reviews and meta-
analyses examining the effect of antenatal behavioural interventions for 
prevention of excessive weight gain during pregnancy, have found these 
interventions significantly decreased gestational weight gain compared with 
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usual care. However, there was no clear reduction in maternal complications or 
adverse neonatal outcomes [100] .  
Bariatric Surgery  
Two recent reviews of case control and cohort trials in patients undergoing 
bariatric surgery before pregnancy, have shown improved fertility rates and 
decrease in maternal and neonatal complications in obese pregnant women 
[101][102]. Sometimes the adverse outcomes are reduced to the frequency of 
adverse events in non-obese patients. Observational studies also consistently 
report a lower prevalence of GDM among women who have had bariatric 
surgery than among obese women who have not undergone this surgery [103]. 
1.4.5 Maternal obesity and risk of diabetes mellitus 
Obese women are at increased risk of GDM compared with normal weight 
women. In a prospective study of more than 16,000 patients with BMI 30-40  
kg/m2, the  odds ratio (OR) for GDM were 2.6 [95% CI 2.4 to 6.0] compared with 
women with BMI < 30 kg/m2 [104]. A meta-analysis, including twenty studies 
was conducted to better estimate the risk of GDM in obese pregnant women 
[105]. The unadjusted ORs of developing GDM were 2.1 (95% CI 1.8 to 2.5) in 
overweight, 3.6 (3.1 to 4.2) in obese, and 8.6 (5.1 to 16.0) in severly obese 
compared with normal BMI women.They concluded that higher the maternal 
weight, higher is the risk for GDM [105]. 
More recently, a meta-analysis was conducted to quantify the risk for GDM 
depending on pre pregnancy BMI [106]. They found the OR for GDM was 1.9 
(95% CI 1.8 to 2.2) for overweight, 3.0 [95% CI 2.3 to 3.9] for moderate obesity 
and 5.6 [95% CI 4.3 to 7.2] for women with morbid obesity (BMI > 40 kg/m2) 
compared with normal weight women [106]. Also, for every 1 kg/m2 increase in 
BMI, the GDM prevalence went up by 0.9% (95% CI 0.7 to 1.1). They 
concluded that the risk of GDM is positively associated with pre-pregnancy BMI 
[106].  
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1.4.6 Visceral Obesity and Risk of Diabetes Mellitus 
A strong association between measures of abdominal obesity (WC, waist:hip 
ratio, and CT-assessed intra-abdominal fat area) and the development of T2DM 
is well established: A meta-analysis of 15 cohorts from 10 longitudinal studies 
suggested there was a strong association between measures reflecting 
abdominal obesity and the incidence of T2DM, and the pooled odds ratio was 
2.1 (95% CI 1.7 to 2.7; P<0.0001) [107]. Also, WC was at least as good as 
other measures in predicting outcome and reducing WC could reduce risk of 
T2DM [107]. Visceral fat assessed by CT remained a significant predictor of 
incident diabetes even after adjustment for BMI, total body fat and 
subcutaneous fat [107]. 
Neeland IJ et al. investigated the associations between adiposity phenotypes 
characterised by excess visceral fat and insulin resistance with the risk of 
incident pre-diabetes and diabetes in 732 obese non-diabetic subjects enrolled 
in the Dallas Heart Study [108]. They concluded that baseline visceral fat mass 
measured by DEXA and MRI imaging but not general adiposity was 
independently associated with risk of development of pre-diabetes and diabetes 
[108]. Kaess BM et al investigated the association of the ratio of visceral 
adipose tissue to subcutaneous adipose tissue with cardiometabolic traits in 
participants from the Framingham Heart study. They concluded that this ratio is 
a correlate of cardiometabolic risk factors reflecting blood pressure, 
dyslipidaemia and insulin resistance, above and beyond BMI [109]  
The pathogenic mechanism linking visceral fat and the onset of diabetes is 
likely to be through the development of insulin resistance. A study in which 63 
patients with T2DM underwent measurements of fat free mass, subcutaneous 
and visceral fat area by MRI and insulin sensitivity showed that visceral fat (VF) 
area was positively related to fasting hyperglycaemia (partial r=0.46; P=0.001)  
and HbA1c (partial r=0.5; P=0.0003) [110]. The interesting result was that 
insulin sensitivity was reciprocally related to VF independent of BMI (partial 
r=0.33; P=0.01). They concluded that, in patients with established T2DM, 
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visceral fat accumulation has a significant negative impact on glycaemic control 
through decreased insulin sensitivity [110]. 
The specific mechanisms by which fat in the visceral compartment confer 
greater risk than subcutaneous fat is unknown. It has been suggested that one 
or more moieties secreted by the visceral adipocyte might mediate insulin 
resistance-for example, free fatty acids (FFA) themselves (portal theory) or the 
adipose tissue related cytokines (adipokines) such as interleukin 1, interleukin 
6, tumour necrosis factor-alpha, resistin, or a reduction in adiponectin. The 
unique anatomical position of the visceral fat depot, with effluent entering the 
liver is also an important consideration [111].  
1.4.7 Lifestyle and other intervention studies in obese pregnant 
women 
The Lifestyle in Pregnancy (LiP) study was a randomised controlled trial among 
360 obese women allocated in early pregnancy to lifestyle interventions with 
diet counselling and physical activities or to the control group [112]. The 
intervention resulted in significantly lower GWG as compared with the control 
group (7.4 kg ± 4.6 versus 8.6 kg ± 4.4, P=0.01) but without improvement in 
rates of clinical pregnancy complications with respect to preeclampsia or 
pregnancy-induced hypertension, GDM, CS, LGA and admission to neonatal 
intensive care unit.  
The UK Pregnancies Better Eating and Activity Trial (UPBEAT) trial concluded 
that a behavioural intervention addressing diet and physical activity in women 
with obesity during pregnancy is not adequate to prevent GDM, or to reduce the 
incidence of LGA babies [113].  
Recently, the results of the “Effect of metformin on maternal and fetal outcomes 
in obese pregnant women (EMPOWaR)” trial were published [114].  The 
estimated effect size of metformin on the primary outcome was not significant 
[114]. There was no evidence of a reduction in the main secondary outcome of 
Homeostatic model for Mathematical Assessment (HOMA) – insulin resistance 
(HOMA-IR) at 36 weeks of gestation. Metformin did not seem to prevent GDM 
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as proportions of women fulfilling either IADPSG or WHO criteria for GDM were 
similar between the groups. Metformin also did not delay the onset of GDM 
[114]. 
1.4.8 C-reactive protein and obesity in pregnancy 
CRP is a sensitive but not a specific marker of inflammation. High levels of CRP 
are associated with infection. Minor elevations of CRP (between 3 and 10 mg/L) 
are associated with low grade inflammation as in obesity and insulin resistance, 
cigarette smoking, diabetes mellitus, hypertension and uraemia. CRP can be 
elevated in obesity and this may at least be in part due to IL-6 secretion by the 
adipose tissue [115]. 
There have been several studies evaluating the associations of CRP with 
insulin resistance and the metabolic syndrome. Festa A et al.  studied the 
relation of body fat mass and distribution to the markers of chronic inflammation 
and concluded that measures of body fat are strongly associated with 
circulating levels of CRP and fibrinogen [116]. Pannacciulli et al. also 
investigated whether CRP concentrations are influenced by body composition, 
insulin resistance and body fat distribution in healthy women and showed an 
independent relationship of central fat accumulation and insulin resistance with 
CRP plasma levels [117].  
Several studies have been conducted to investigate the role of inflammatory 
markers as predictors of T2DM among healthy women. Hu FB et al. conducted 
a prospective case-control study of inflammatory markers as predictors of 
T2DM among healthy women and concluded that elevated CRP levels are a 
strong independent predictor of T2DM [118]. In a similar study in 1992 in 
healthy middle-aged women in the US, Pradhan AD et al. concluded that 
elevated levels of CRP and IL-6 predict the development of T2DM [119]. 
There have been a few studies to determine whether CRP is elevated in 
patients with GDM with contradictory results. In one such study by Retnakaran 
R et al., pre-pregnancy BMI emerged as a most important determinant of CRP 
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concentration, whereas glycaemic tolerance status was not a significant factor 
[120].  
Leipold H et al. measured CRP concentrations longitudinally throughout 
pregnancy and concluded that, in women with GDM, the CRP concentration is 
primarily related to the degree of adiposity until the second trimester and that 
thereafter impaired glucose metabolism appears to be a predominant predictor 
of changes in CRP [121]. Wolf M et al. investigated the association between 
first trimester CRP levels with the subsequent development of GDM and found 
that first trimester CRP levels were significantly increased among women who 
subsequently developed GDM compared with control subjects. The risk of 
developing GDM among women in the highest CRP tertile was higher 
compared with the lower tertile. When BMI was included in the model, however, 
the association between increased CRP and GDM was attenuated [122]. A 
similar positive association between CRP and GDM risk was also seen in 
studies by Qui C et al. [123].  
1.5 Safety data for the use of metformin in pregnancy 
Metformin is classified by the FDA as a Category B drug in pregnancy i.e. no 
evidence for risk in humans [124] . Metformin is widely used in clinical practice 
in the management of DM in pregnancy in many centres of the world and its use 
in the UK is approved and recommended in the NICE guidance [125]. There is 
data from over 20 years of use of metformin in women with GDM or T2DM in 
pregnancy in South Africa [126]. Glueck et al. prospectively assessed growth 
and motor-social development during the first 18 months of life in 126 infants 
born to 109 mothers with polycystic ovaries who conceived on metformin and 
continued metformin throughout pregnancy [42]. They concluded that metformin 
reduced the risk of development of GDM in women with polycystic ovaries and 
that it was not teratogenic and did not adversely affect the length, weight, 
growth and motor-social development at 18 months of life [42]. 
The Metformin in Gestational Diabetes – The Offspring Follow Up study (MiG 
TOFU) assessed the body composition of 154 babies of mothers who were 
exposed to metformin in pregnancy, at 2 years of age. This was to assess the 
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potential effects on growth of the baby, as metformin is known to cross the 
placenta [127].  No difference was observed between the two groups for central 
fat measures, total fat mass or percentage body fat. They found that children 
exposed to metformin had larger measures of subcutaneous fat, but overall 
body fat was the same as in children whose mothers were treated with insulin 
alone [127]. Compared with the insulin group, the metformin group had larger 
upper arm circumferences and bigger biceps and sub scapular skin folds, 
indicating a more favourable pattern of fat distribution for children exposed to 
metformin. They suggested further follow-up is required to examine whether 
these findings persist into later life and whether children exposed to metformin 
will develop less visceral fat and be more insulin sensitive [127]. Also, blood 
pressure results obtained at 2 years in a large cohort of children exposed to 
metformin (170 children) in the MiG trial were comparable to published norms 
and were no different in those children whose mothers had received either 
metformin or insulin [128]. Reassuringly, there is no clinical evidence of 
abnormalities in growth or motor development in infants exposed to metformin 
in utero [129]  . 
Previous studies have demonstrated that in women with T2DM who take 
metformin in pregnancy, there is an increased metformin clearance due to 
enhanced renal elimination. Therefore, metformin doses may have to be 
increased by at least 20% in late pregnancy to maintain a therapeutic effect 
[130].  
1.6 Aims and objectives of this study 
Literature review has revealed that obesity in pregnancy contributes to 
increased morbidity and mortality for both mother and baby [67]. There is 
evidence in non-pregnant individuals that body fat distribution, especially 
visceral fat, is a more important risk factor for the development of T2DM than 
the BMI [107][108]. However, there are no such studies published in pregnancy.  
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1.6.1 Aims of the VFM study 
1. To investigate whether a higher baseline VFM confers a higher risk of 
GDM in obese pregnant women.  
2. To develop a mathematical model to predict GDM and LGA babies in 
obese pregnant women in early pregnancy using machine learning. 
 
1.6.2  Objectives of the VFM study 
1. To set up a clinical study in obese non-diabetic pregnant women 
attending an antenatal weight management clinic. 
2. To measure the body composition of women at recruitment into the 
study, between 12 to 18 weeks of gestation. 
3. To record the results of the OGTT conducted at 28 weeks of gestation. 
4. To compare the baseline characteristics and body composition between 
women who developed GDM and those who did not. 
5. To perform statistical analysis and investigate whether women with VFM 
≥ 75th percentile are at higher risk of GDM. 
6. To develop a mathematical model to predict GDM and LGA babies 
incorporating VFM in early pregnancy in addition to classical risk factors. 
Lifestyle intervention programmes in pregnancy in obese women have shown 
no evidence of benefit for the neonate. Since insulin resistance is increased in 
obesity and is strongly associated with birth weight, metformin is a rational 
choice to improve outcomes in this population. 
1.6.3 Aims of the Metformin in Obese non-diabetic Pregnant women 
(MOP) Trial 
1. To investigate whether metformin improves pregnancy outcomes (incidence 
of LGA (≥90% birth weight centile) babies, onset of maternal GDM, 
hypertension, preeclampsia, macrosomia, shoulder dystocia, admission to 
SCBU in obese non-diabetic women. 
We aim to compare perinatal outcomes in women randomised to the two groups 
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                Group 1: Standarised life style intervention and placebo 
                Group 2: Standarised life style intervention and metformin 
2. To determine whether there is an association between baseline insulin 
resistance and adverse pregnancy outcomes such as gestational diabetes, 
pregnancy-induced hypertension and preeclampsia. 
3. To investigate whether metformin will improve body fat distribution with 
particular emphasis on VFM during pregnancy          
4.  To examine the hypothesis that metformin is most effective in those patients 
with the highest baseline insulin resistance and treatment with metformin 
throughout pregnancy will reduce the risk of gestational diabetes in this group of 
women. 
 
1.6.4 Objectives of the MOP Trial 
1. To set up a randomised controlled trial in obese non-diabetic pregnant 
women with BMI ≥ 35 kg/m2. 
2. To obtain ethical approval and Clinical Trial Authorisation from Medicines 
and Health Regulatory Agency (MHRA). 
3. To organise manufacture and packaging of placebo to match the metformin. 
4. To obtain informed written consent of each participant. 
5. To randomise recruited women to metformin or placebo. 
6. To organise Oral glucose tolerance test (OGTT), fasting insulin and other 
blood tests at recruitment. 
7. To measure the body composition of women at recruitment and repeat at 22 
weeks, 28 weeks, 36 weeks and postnatal. 
8. To record the results of the OGTT conducted at 28 weeks of gestation. 
9. To record all adverse events in the participants. 
10. To perform statistical analysis and compare the baseline characteristics, 
body composition, pregnancy and neonatal outcomes between the women 
randomised to metformin or placebo.  
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11. To calculate insulin resistance at booking and 28 weeks of gestation using 
the Homeostatic model assessment (HOMA) model. 
12. To perform statistical analysis to compare the change of fasting insulin, 
insulin resistance, visceral fat and CRP at 28 weeks of gestation from 
baseline in the metformin and placebo groups. 
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2     VISCERAL FAT MASS STUDY 
 
This chapter outlines the risks of obesity in pregnancy for the mother and the 
baby, the rationale and aims of the visceral fat mass (VFM) study, and 
discusses the methodology of this study and the results obtained. The body 
composition of 302 obese pregnant women, including VFM was assessed at 12-
18 weeks of gestation. The maternal and neonatal outcomes were compared 
between the group of women who developed diabetes and those who did not. 
This chapter also discusses the importance of body fat distribution of the 
women, and in particular, VFM in early pregnancy and the risk of subsequent 
GDM.  
This chapter also describes how a mathematical model was developed using 
machine learning, to predict GDM and birth centile classes in early pregnancy in 
obese women. VFM, which is a novel risk factor for GDM, was used in addition 
to conventional risk factors.  
 
2.1 Introduction 
There is substantial evidence that obesity in pregnancy contributes to increased 
complications for both mother and baby [67]. Obese women are at increased 
risk of GDM compared with normal weight women [104][105][106]. The 
complications of GDM are mainly due to maternal hyperglycaemia resulting in 
fetal hyperinsulinemia and macrosomia. This increases the risk for shoulder 
dystocia, fracture of the clavicle and more seriously, brachial plexus palsy 
during delivery of the baby [104]. Besides this, there is also a risk to the mother 
and offspring of diabetes and cardiovascular disease in later life [131]. A meta-
analysis on studies conducted in patients with diabetes outside of pregnancy, 
suggested there was a strong association between measures reflecting 
abdominal obesity and the incidence of T2DM, and the pooled odds ratio was 
2.1 (95% CI 1.7 to 2.7, P<0.0001) [107]. Similarly, as discussed in the literature 
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review, Neeland et al. concluded that baseline VFM measured by DEXA and 
MRI imaging but not general adiposity was independently associated with risk of 
development of pre-diabetes and diabetes [108]. 
Machine learning algorithms are being increasingly used in clinical medicine. In 
pregnancy, they are currently used to predict genetic disorders like Down‟s 
syndrome or trisomy 21 and Edward‟s syndrome or Trisomy 18. The first 
trimester screening for Downs syndrome uses an algorithm and detects 90% of 
the Down‟s syndrome fetuses prenatally with a 5% false positive rates [132]. 
 
2.2  Rationale 
There is no published data on the possible association of VFM in pregnancy 
and the risk of GDM, despite these consistent results outside pregnancy. 
Hence, the aim of the study was to evaluate the relation of body fat distribution, 
particularly VFM and the risk of GDM in a cohort of obese women with no 
known diabetes. The study also investigated whether a higher VFM in early 
pregnancy would confer a higher risk of subsequent GDM. 
This study also aimed to develop a mathematical model which could predict 
GDM and LGA babies in obese pregnant women using machine learning. It may 
be clinically useful to identify women at greatest risk of GDM or a LGA baby 
early in their pregnancy, as lifestyle and pharmacological interventions to 
improve baby outcomes could then be utilised in this high risk group [113]. 
Metformin, for example can be used to reduce the risk of GDM in women with 
polycystic ovaries [133]. 
The current method of GDM screening is based on risk factors like maternal 
age, BMI, history of polycystic ovarian syndrome, family history of diabetes, 
previous GDM, ethnicity and previous macrosomia. This method provides a 
detection rate of approximately 60% with a 40% false positive rate [125][114]. 
Currently, those women identified with even a single risk factor undergo an 
OGTT at 24-28 weeks gestation. Risk stratification for GDM early in pregnancy 
may reduce the need for OGTT in women at low risk resulting in savings in 
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costs and in burdensome diagnostic testing. Only 24% of obese [114] or very 
obese women [134] developed GDM in the control arms of two recent 
prospective trials investigating the possible beneficial effects of metformin in 
these women. Risk stratification in early pregnancy may help to avoid extra 
clinic visits and extra scans in low risk obese women. 
 
2.3  Aims of the study 
1. To investigate whether a higher baseline VFM confers a higher risk of 
GDM in obese pregnant women.  
2. To develop a mathematical model to predict GDM and LGA babies in 
obese pregnant women in early pregnancy using machine learning. 
 
2.4  Objectives of the study 
1. To set up a clinical study in obese non-diabetic pregnant women 
attending an antenatal weight management clinic. 
2. To measure the body composition of women at recruitment into the 
study, between 12 to 18 weeks of gestation. 
3. To record the results of the OGTT conducted at 28 weeks of 
gestation. 
4. To compare the baseline characteristics and body composition 
between women who developed GDM and those who did not. 
5. To perform statistical analysis and investigate whether women with 
VFM ≥ 75th percentile are at higher risk of GDM. 
6. To develop a mathematical model to predict GDM and LGA babies 
incorporating VFM in early pregnancy in addition to classical risk 
factors. 
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2.5 Material and Methods 
2.5.1 Ethical Approval 
The London-Surrey Borders Research Ethics committee advised us that ethical 
approval was not required for the study as all women would only undergo 
routine clinical investigations and management (See Appendix A.1). No study 
specific procedure was undertaken on any of the participants. 
 
2.5.2 Inclusion criteria 
 Obese pregnant women          
 Gestation between 12 and 18 weeks 
2.5.3 Exclusion criteria       
 Pre-existing established diabetes 
 Multiple fetuses  
 Moving out of area for pregnancy management 
2.5.4 Study design 
This study was conducted at St Helier Hospital, Surrey in the UK (Figure 2-1). 
302 women attending the antenatal clinic at St Helier Hospital and fulfilling the 
eligibility criteria were enrolled in this study. I recorded their demographic, 
medical and obstetric history. All women received standardised personal advice 
on healthy eating and carbohydrate content of food, emphasizing low glycaemic 
index foods. They were encouraged to undertake 30 minutes of physical activity 
at least 5 days in a week. 
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Figure 2-1: Flowchart for women participating in the Visceral Fat Mass study 
The flowchart shows that 302 women were enrolled into the VFM study. 
I performed the body composition analysis on all women using a machine called 
Inbody 720R on enrolment into the study. The schedule of clinical assessments 
is shown in Table 2-1. I assessed all women clinically including weight and 
blood pressure. The midwife carried out the fetal assessment. They also had a 
75g OGTT at 24-28 weeks of gestation, as per the hospital protocol for a 
pregnant woman with high BMI. The WHO 1999 criteria for the diagnosis of 
GDM was used [135].  
Women with abnormal results of the OGTT were referred to the joint antenatal 
diabetes clinic and given dietitian input and advised to commence home 
glucose monitoring. If target blood glucose values were not achieved on diet 
Obese pregnant women  
N=302 obese pregnant women enrolled 
Exclude established diabetes  
Oral GTT at 28 weeks gestation 
Group 1 (GDM, n=72) Group 2 (no GDM, n=230) 
Joint antenatal Diabetes clinic         
Commence home glucose monitoring, 
dietitian input, Metformin/Insulin therapy 
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alone, metformin was started at a dose of 500mg twice a day and the dose was 
titrated up to a maximum of 2500 mg per day to achieve target home blood 
glucose monitoring values (Fasting glucose < 6mmol/l, 1 hour postprandial < 
8mmol/l and 2 hour postprandial levels < 7mmol/l). Fasting was defined as an 
overnight fast of 10-12 hours. Insulin was added if hyperglycaemia persisted in 
spite of maximum doses of metformin or the patient was intolerant to metformin 
or did not wish to take it. Some women had a normal OGTT result at 28 weeks, 
but later developed GDM as diagnosed by glucose monitoring. They were 
advised glucose monitoring for persistent glycosuria or after the growth scan 
showed a macrosomic baby. 
Table 2-1: Schedule of visits for participants of the visceral fat mass study 
Onset of GDM, pregnancy induced hypertension (PIH), preeclampsia, deep 
venous thrombosis and mode of delivery were recorded for each participant. 
Birth weight, neonatal hypoglycaemia, neonatal hyperbilirubinemia, major 
Visit No 
 
 
1 
Screening and 
recruit 
2 
 
 
3 
 
 
4 
Week of gestation 12-18 28 weeks 36 weeks Term 
Inclusion/ Exclusion  X    
Medical and obstetric History X    
Blood Pressure, Urine , fetal 
check 
X 
X 
 X 
X 
X 
 
Body Composition X    
OGTT  X 
 
  
Delivery and baby details    X 
 
 47 
malformations, shoulder dystocia and admission to special care baby unit were 
also recorded. In patients who develop GDM, the OGTT was repeated 6 weeks 
postnatal to screen for persistent glucose intolerance. 
 
2.5.5 Statistical Analysis 
The statistical analysis was performed by using R. Each continuous variable 
was tested individually for normality using the skewness and kurtosis test. The 
maternal baseline characteristics, pregnancy and neonatal outcome in patients 
developing GDM (Group 1, n=72) were compared with those with normal 
glucose tolerance (Group 2, n=230). The normally distributed data were 
expressed as mean ± standard deviation. Parametric tests like Welch‟s t-test, 
which is an adaptation of Student‟s t-test was used to compare the means of 
two groups as it is more reliable when the two samples have unequal variances 
and unequal sample sizes These tests are also called as “unpaired” or 
“independent samples” t-tests as they are typically applied when the statistical 
units underlying the two samples are non-overlapping. Fisher‟s test was used to 
compare categorical variables and the level of significance is P<0.05. The 
association between variables in a normally distributed data was investigated 
with the Pearson‟s correlation coefficient. 
Data which was not normally distributed has been expressed as median and 
interquartile range (IQR). The dataset was divided by 3 quartiles (Q1, Q2 and 
Q3) to four different parts. The data lying between the first and third quartile 
form the interquartile range. The non-parametric tests like Mann-Whitney U test 
was used to explore the difference between the variables in the two groups with 
and without GDM and the level of significance is P<0.05. The association 
between variables in a data not normally distributed was investigated with the 
Spearman‟s rank correlation.  
Data mining and analysis 
Principal Component Analysis (PCA) was used as part of the statistical analysis 
of the data. PCA is an unsupervised multivariate statistical technique for 
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identifying correlations between samples using a smaller number of 
uncorrelated variables called “Principal Components” from a large set of data. In 
PCA, the dataset is transformed from its original coordinate system to a new 
coordinate system. The new coordinate system is chosen by the data itself. The 
first new axis is chosen in the direction of the most variance in the data. The 
second axis is orthogonal to the first axis and in the direction of an orthogonal 
axis with the largest variance. This procedure is repeated for as many features 
as in the original data.  The majority of the variance is contained in the first few 
axes and the rest of the axes can be ignored reducing the dimensionality of the 
data. PCA makes the data interpretation easier by reducing its dimensionality 
[136].  
Machine learning is the method that turns data into information. Supervised 
learning asks the machine to learn from our data when we specify a target 
variable. The machines task is to divine some pattern from the input data to get 
the target variable [136]. We used various algorithms like Decision Trees and 
Random Forest to develop the model [137] [138]. 
Random Forest and Decision Tree Modelling 
Random Forest (RF) is a family of algorithms for regression and classification 
that works by constructing a “forest” of decision trees and outputting the class 
that appeared most times. The general idea behind the algorithm is constructing 
many classification trees [139]. Each tree is given the same input vector and 
outputs predicted class. The final class prediction is the one that appeared as a 
result for most predictive trees. RF is an ensemble method based on bootstrap 
aggregation. This method constructs multiple versions of the training data by 
sampling with replacement (bootstrapping), creates a model and makes 
predictions for all of them and combines the predictions [136].  
RF was implemented with 200 trees using the “randomForest” function from the 
“randomForest” package in R [140]. The performance of the developed model 
was validated using the Monte Carlo cross validation method [141]. For K=100, 
the samples from each dataset were randomly distributed into training and 
testing datasets in 100 different splits. Then, the performance was calculated as 
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an average of the performance of the 100 models. Firstly, the input dataset (n = 
302) was randomly split over 100 iterations into a training dataset, which 
contained 70% of the samples (n = 227), and a testing dataset (n = 75) 
composed by the remaining samples. The training dataset was then used to 
build the model while the testing dataset was used to calculate the performance 
of such model. As the performance was calculated as a mean of 100 
individually trained and optimised models, the outcome was less likely to suffer 
from optimistic prediction accuracy and/or over-fitting. 
Decision trees are constructed by analysing a set of training examples for which 
the class labels are known. They are then applied to classify new examples. A 
decision tree classifies data items by asking a series of questions about the 
features associated with the items. Each question is contained in a node, and 
every internal node points to one child node for each positive answer to its 
question. There is a hierarchy in the questioning, encoded as a tree. In its 
simplest form, yes-or-no questions are asked, and each internal node has a 
“yes” child and a “no “child. An item is sorted into a class as it passes down 
from the topmost node, the root, to a node without children, a leaf, depending 
on the answers. The item is then assigned to the class that has been 
associated with the leaf it reaches. Decision trees are easy to interpret as they 
combine simple questions on the data in an understandable way [137]. 
 
 
 
2.6 Results 
The distribution of the continuous variables was analysed by performing the 
skewness test. Most of the continuous variables like age, weight, HbA1c, 
percentage body fat, visceral fat area, 2-hour blood glucose values after OGTT 
and baby birth weight had a normal distribution. BMI, WHR and fasting glucose 
values at the OGTT did not have a normal distribution (Table 2-2).  
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Table 2-2: Test of normality for maternal and neonatal characteristics 
Most of the variables were distributed normally except body mass index, waist hip ratio and 
fasting blood glucose. 
Maternal Baseline Characteristics 
302 obese pregnant women were enrolled into the study. The median age of 
the group was 31 years (interquartile range 26-34 years) and the median BMI 
was 38.3 kg/m2. (interquartile range 36.7-41.6). Most the women were 
Caucasians (74.5%). Seventy-two patients of the 302 enrolled patients were 
diagnosed to have gestational diabetes (23.8%). Women who developed GDM 
were older (32.1 ± 5.5 years vs. 29.6 ± 5.8 years, P<0.05), had a higher median 
BMI (40.6 kg/m2 [37.5-43.4] vs. 38 kg/m2 [36.3-40.9], P<0.05) and greater 
Variable Minimum Quartile
1 
Median Mean Quartile
3 
Maximum Skew Normality 
Age (years) 16 26 31 30.21 34 43 -0.07 Yes 
Weight (kg) 73.5 95.4 104.2 105.1 112.4 157.2 0.47 Yes 
HbA1c 
(mmol/mol) 
28 33.2 37 37.7 42 50 0.29 Yes 
Body Mass 
Index (Kg/m
2
) 
31.4 36.7 38.3 39.34 41.6 63.9 1.37 No 
Percentage 
Body fat (%) 
35.1 47.2 50 49.31 51.6 57.9 -0.61 Yes 
Waist Hip 
Ratio 
0.89 0.96 0.99 0.99 1.3 1.43 1.91 No 
Visceral  fat  
Mass (units) 
113.9 164.3 182.8 187.5 207.7 351.7 0.88 Yes 
Fasting blood 
glucose                
( mmol/l) 
3.5 4.3 4.6 4.64 4.9 6.9 1.13 No 
2-hour blood 
glucose 
(mmol/l) 
3 4.8 5.4 5.57 6.2 11.8 0.87 Yes 
Birth weight 
(grams) 
1100 3141 3500 3494 3882 5040 -0.18 Yes 
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waist:hip ratio (1[0.99-1.04] vs. 0.98 [0.95-1.02], P<0.05] when compared with 
women who did not develop GDM (“no GDM” group). They also had a 
significantly greater visceral fat mass (199.2 ± 40.5 units vs. 183.8 ± 31.5 units, 
P<0.05).  However, the total percentage body fat was similar in both groups 
(49.8 ± 3.5 % vs. 49.2 ± 3.6%, P=0.19) (Table 2-3). 
Table 2-3: Maternal age and body composition: Statistical comparison between 
the GDM and no GDM groups 
 
 
GDM group  
n=72 
Mean (± SD) a 
Median (IQR)b 
no GDM group 
n=230 
Mean (± SD) a 
Median (IQR)b 
 
P value 
 
Age (years) 
 
 
32.1(± 5.5) 
 
29.6 (± 5.8) 
 
<0.05a 
Weight in early 
pregnancy (kg) 
 
107.3 (± 16.4) 103.3 (± 14.9) 0.07a 
Percentage Body Fat 
(PBF) (%) 
 
49.8 (± 3.5) 49.2 (± 3.6) 0.19a 
Visceral Fat Mass c 
(units) 
 
199.2 (± 40.5) 183.8 (± 31.5) <0.05a 
BMI (kg/m2) 40.6 (37.5-43.4) 38 (36.3-40.9) <0.05b 
 
Waist-Hip ratio  
 
1 (0.99-1.04) 0.98 (0.95-1.02) <0.05b 
  
a 
Independent two samples t-test, 
b 
Mann-Whitney U test, IQR- Interquartile range, 
c 
Normal 
value < 100 units. Women who developed GDM were significantly older, had a higher body 
mass index, waist-hip ratio and visceral fat area. However, weight in early pregnancy and 
percentage body fat was not significantly different in both the groups. 
Figure 2-2 compares the age of women between the 2 groups. The boxplot 
depicting the age of women who developed GDM (GDM+) has a higher median 
than the boxplot of the age of women who did not develop GDM. It also shows 
the interquartile range. 
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Figure 2-2: Comparison of the age of women - GDM and no-GDM groups 
GDM+ is the group of women who developed GDM. GDM- is the group of women who did not 
develop GDM. The median depicting the age of women with GDM was higher than the median 
depicting the age of women without GDM. 
Figure 2-3 compares the BMI of women between the 2 groups. The boxplot 
depicting the BMI of women who developed GDM (GDM+) has a higher median 
than the boxplot of the BMI of women who did not develop GDM (Figure 2-3). 
 
Figure 2-3: Comparison of the BMI of women - GDM and no-GDM groups   
The median of the box plot depicting the BMI of women with GDM was higher than the median 
of the box plot depicting the BMI of women without GDM. 
Figure 2-4 shows that the boxplot depicting the VFM of women who developed 
GDM (GDM+) has a higher median than the boxplot depicting the VFM of 
women who did not develop GDM.  
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Figure 2-4: Comparison of the VFM between the GDM and no-GDM groups 
The median of the box plot depicting the VFM of women with GDM was higher than the median 
of the box plot depicting the VFM of women without GDM. 
The ethnic distribution of women in both groups was not very different (Table 
2-4). Women with GDM were more likely to have a history previous GDM when 
compared with women without GDM. Women with history of GDM in any 
previous pregnancy were treated as having GDM in all subsequent pregnancies 
according to hospital guidelines.  
 Table 2-4: Maternal baseline characteristics: GDM and no GDM groups 
 a
 Fisher‟s exact test. Women who developed GDM were more likely to have polycystic ovaries, 
family history of diabetes and previous GDM. 
 
 
 
GDM group     
(n=72) 
no GDM group       
(n=230) 
P value a 
Ethnicity n (%) 
            Caucasian 
             Asian 
             Black 
             Other 
 
60 (83.3) 
7 (9.7)                                 
3 (4.2)                               
2 (2.8) 
 
165 (71.7)                             
30 (13)                            
27 (11.7)                                
8 (3.5) 
 
0.06                
0.54                   
0.07                     
0.8 
Polycystic ovaries, n (%) 
15 (20.8) 16(7) <0.05 
Family history of DM n (%) 
41(56.9) 79(34.3) <0.05 
Previous GDM n (%) 
12 (16.8) 0 <0.05 
Smokers n (%) 
4 (5.6) 16 (7) 0.79 
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The OGTT results showed, as expected, significantly higher median fasting 
glucose (4.8 mmol/l [4.6-5.3] vs. 4.6 mmol/l [4.3-4.8], P=0.0001) and higher 
mean 2-hour glucose (6.3 ± 2.9 mmol/l vs. 5.4 ± 1.3 mmol/l, P=0.0004) in 
women who developed GDM compared with women who did not ( Table 2-5). 
 Table 2-5: OGTT results at 28 weeks’ gestation: Statistical comparison between 
the GDM and no GDM groups 
 a 
Independent two samples t-test, 
b 
Mann-Whitney U test, IQR - interquartile range. The median 
fasting glucose and the mean 2-hour glucose were higher in the women who developed GDM 
as compared to the women who did not develop GDM. 
Pregnancy induced hypertension, preeclampsia and thromboembolism were not 
significantly different between the two groups. Similarly, the rates of Caesarean 
section were also not significantly different between the groups. Women with 
GDM showed a trend towards more emergency Caesarean sections (30.6%) 
compared to women without GDM (23%). However, there was a trend towards 
lesser instrumental deliveries in the women with GDM (4.2%) as compared to 
the women without GDM (10%), and the trend persisted even after excluding 
women who had emergency Caesarean sections (Table 2-6). 
 
 
 
 
      GDM group  
         (n=72) 
    
      Mean (± SD) a 
      Median (IQR) b 
     no GDM group, 
           n=230 
       
      Mean (± SD) a 
      Median (IQR) b 
 
 
P value 
 
 
 OGTT-Fasting glucose 
value (mmol/l) 
 
 
4.8 (4.6-5.3) 
 
4.6 (4.3-4.8) 
 
<0.05b 
OGTT-2 hour glucose 
value (mmol/l) 
 
 
6.3 ( ± 2.9) 
 
5.4 ( ± 1.3) 
 
<0.05a 
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Table 2-6: Maternal outcomes: Statistical comparison between the GDM and no 
GDM groups. 
a
 Fisher‟s exact Test. Maternal outcomes like PIH, preeclampsia and DVT were not significantly 
different between groups. There was also no statistical difference in the number of women 
delivering by Caesarean section between the two groups. 
The difference in mean birth weight between the groups was not significantly 
different (3452.8 ± 626 g vs. 3506.7 ± 564 g, P=0.5).  Similarly, the percentage 
of LGA babies was similar in both groups (18.3% vs. 18.1%, P=1). There was 
also no significant difference in the rate of admission to neonatal care units 
(11.2% vs. 9.6%, P=0.7), neonatal jaundice (4.2% vs. 0.8%, P=0.08) and 
shoulder dystocia (0% vs. 0.4%, P=1) between the groups. More babies in the 
GDM group had neonatal hypoglycaemia (4.2% vs. 0.4%) as compared to no 
GDM group and this difference reached statistical significance (P=0.04) (Table 
2-7). 
 
 
 
 
 GDM group 
n=72 
 
no GDM group 
n=230 
P value 
a 
PIH, n (%) 
8 (11.1) 21 (9.1) 0.6 
Preeclampsia n (%) 
1 (1.4) 2 (0.9) 0.6 
 
Mode of Delivery:  n (%) 
- Vaginal 
- Instrumental 
- Elective C/section 
- Emergency C/section 
    
 
 34 (47.2)                                           
3 (4.2)                                          
13 (18.1) 
22 (30.6) 
 
 
122 (53)                                         
23 (10)                         
32 (13.9)                                       
53 (23) 
 
 
0.4                     
0.2                    
0.5                 
0.2 
 Deep vein thrombosis n (%) 
 
0 1 (0.4) 0.6 
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Table 2-7: Neonatal outcomes: Comparison between the groups 
a 
Independent two samples t-test, 
b 
Fisher‟s exact test, 
c
 Capillary glucose <2.6mmol/l . There 
was no significant difference in any of the neonatal outcomes except neonatal hypoglycaemia. 
More babies of mothers who developed GDM had hypoglycaemia at birth 
 
As discussed earlier, women diagnosed with GDM were referred to the 
specialist antenatal diabetes clinic where they were treated intensively with diet, 
metformin alone or in combination with insulin, until euglycaemia was achieved. 
This intensified treatment for gestational diabetes was responsible for the 
minimal differences seen in neonatal outcomes in women with and without 
GDM in my study. There were no still births in my study. 
Correlations between variables 
The correlation of VFM obtained at recruitment with the 28-week glucose values 
obtained during OGTT is shown in  Table 2-8. A moderate positive correlation 
was seen between VFM and fasting glucose values in Group 1 (r=0.32; 
P=0.002) .There was a weak positive correlation between VFM and fasting 
glucose in the whole cohort. 
 
GDM group 
(n=72) 
Mean (± SD) a
 
 
no GDM group                                                
(n=230) 
Mean (± SD) a 
P 
value 
Birth weight (g) 
3452.8 ± 626 3506.7 ± 564 0.5a 
Large for gestational age, n (%) 
13 (18.3) 42 (18.1) 0.96b 
Admissions to Neonatal Intensive 
Care Unit, n (%) 
8 (11.2) 22 (9.6) 0.7b 
Major malformations n (%) 
0 0 1.00b 
Neonatal hypoglycaemia c, n (%) 
3 (4.2) 1 (0.4) 0.04b 
Neonatal hyperbilirubinemia n(%) 
3 (4.2) 2 (0.8) 0.08b 
Shoulder dystocia n (%) 
0 1 (0.4) 0.57b 
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 Table 2-8: Correlation of VFM with OGTT test results 
 a 
Pearson‟s correlation coefficient, 
b
 Spearman‟s rank correlation. A moderately positive 
correlation was seen between visceral fat mass and fasting glucose in GDM group. 
There was a weak positive correlation between PBF and the fasting glucose in 
all groups. No such correlation was seen with the 2-hour glucose values and 
PBF in the whole group or each group individually ( Table 2-9). 
 Table 2-9: Correlation of PBF with OGTT test results  
 a 
Pearson‟s correlation coefficient, 
b
 Spearman‟s rank correlation. A weak positive correlation 
was seen between percentage body fat and fasting glucose in all groups. 
 
Correlation coefficient 
Pearson’s a 
Spearman’s b 
P value 
VFM versus fasting glucose (whole) 
0.18b <0.05 
VFM versus 2-hr glucose (whole) 
0.09a 0.1 
VFM versus fasting glucose (no GDM) 
0.14 b 0.07 
VFM versus 2-hr glucose (no GDM) 
0.008a 0.9 
VFM versus fasting glucose (GDM) 
0.32b <0.05 
VFM versus 2-hr glucose (GDM 1) 
-0.19a 0.1 
 
Correlation coefficient 
Pearson’s a 
Spearman’s b 
P value 
PBF versus fasting glucose (whole) 
0.14b 0.01 
PBF versus 2-hr glucose (whole) 
0.04a 0.5 
PBF versus fasting glucose (no GDM) 
0.14b 0.03 
PBF versus 2-hr glucose (no GDM) 
0.04a 0.7 
PBF versus fasting glucose (GDM) 
0.24b 0.03 
PBF  versus 2-hr glucose (GDM)  
0.13a 0.3 
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There was a moderate positive correlation between maternal BMI and HbA1c 
(r=0.39; P<0.05), and a strong positive correlation between VFM and HbA1c 
(r=0.47; P<0.05 in women who developed GDM (Figure 2-5). However, no 
significant correlation was found between total PBF and HbA1c (r=0.16; P= 0.2).  
 
 
 
Figure 2-5: Correlation of HbA1c and VFM in women who developed GDM      
A strong positive correlation was seen between VFM and HbA1c in GDM group 
 
A weak positive correlation was seen between maternal BMI and VFM at 
recruitment with birth weight, for the whole cohort and in the no GDM group. 
However, no such correlation was seen between maternal BMI and VFM at 
recruitment with birth weight in the group of women who developed GDM in 
pregnancy (Table 2-10). 
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Table 2-10: Correlation between BMI, PBF and VFM with the baby birth weight 
a 
Pearson‟s correlation coefficient, 
b
 Spearman‟s rank correlation. A weak positive correlation   
was seen between maternal BMI and VFM with birth weight, for the whole cohort and in the no 
GDM group 
In the overall cohort, 72 of the 230 women developed GDM. Women who 
developed GDM were more likely to have a baseline VFM ≥ 75th percentile as 
compared to women who did not (43.1% vs. 19.5% [Odds ratio 3.1(1.8 to 5.5)], 
P=0.0001)(Table 2-11). 
Table 2-11: Baseline VFM and subsequent GDM 
 More women in the GDM group had baseline VFM ≥ 75th percentile and VFM ≥ 90th percentile 
as compared to women who did not develop GDM. 
 
Correlation coefficient 
Pearson’s a 
Spearman’s b 
P value 
BMI versus birth weight (whole) 
r=0.13b 0.03 
PBF versus birth weight (whole) 
r=0.02a 0.7 
VFM versus birth weight (whole) 
r=0.17a <0.05 
BMI versus birth weight, no GDM group 
r=-0.13b 0.04 
PBF versus birth weight, no GDM group 
r=0.03a 0.65 
VFM versus birth weight, no GDM group 
r=0.18a <0.05 
BMI versus birth weight, GDM group  
r=0.13b 0.2 
PBF versus birth weight, GDM group 
r=-0.02a 0.8 
VFM versus birth weight, GDM group 
r=0.19a 0.1 
Measure 
GDM (n=72) No GDM (n=230) Odds ratio 
(95%CI) 
P 
value 
 
 VFM ≥ 75
th  
percentile, n (%) 
 
 
31 (43.1) 45 (19.5) 3.1(1.8 to 5.5) <0.05 
VFM ≥ 90th  
percentile, n(%) 
 
 
11 (15.3) 13 (5.6) 3.0(1.3 to 7) 0.01 
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A subgroup analysis was also performed based on ethnicity comparing BMI, 
WHR and VFM in Caucasians versus Asians in the group of women who 
developed GDM, in order to evaluate whether ethnicity influences the relation of 
body fat to GDM. We have reports in literature, outside pregnancy, that Asians 
develop type 2 diabetes at a lower BMI as compared to Caucasians. The VFM 
was significantly higher in Caucasians than in the Asians in this group (Table 
2-12). 
Table 2-12: Comparison of BMI, WHR and VFM in Caucasians and Asians who 
develop GDM 
 
Caucasians, n=60 
Mean (± SD) a 
Median (IQR)b 
Asians, n=7 
Mean (± SD) a 
Median (IQR)b 
P value 
 
 
Body Mass 
Index (BMI) 
41 (37.7-43.6) 37.5 (35.8-40.8) 0.16b 
 
Waist-Hip Ratio 
1 (0.98-1.04) 1 (0.98-1.04) 0.1b 
Visceral Fat 
Mass (VFM) 
202.3 ± 40.5 167.9 ± 36.4 0.03a 
 
a
 Independent two samples t-test, 
b 
Mann-Whitney U test, IQR-interquartile range. The visceral 
fat mass was significantly higher in Caucasians than the Asians in the group who develop GDM 
 
Results of Principal Component Analysis 
Principal Component Analysis was carried out by reducing the variables into 
two Principal Components and plotting the variance. Maternal age, BMI, family 
history of diabetes, polycystic ovarian syndrome which are classical risk factors 
for GDM were combined with body composition measurements like PBF, 
skeletal muscle mass, WHR and VFM as input data. There were no distinct 
clusters of samples seen between GDM and no GDM and hence no evident 
separation in Principal Component 1 (PC1) versus Principal Component 2 
(PC2), PC1 versus Principal Component 3 and PC2 versus PC3 (Figure 2-6, 
Figure 2-7 & Figure 2-88). 99.7% of the variance was captured in PC1, 0.2% of 
the variance was captured in PC2 and 0.1% in PC3. 
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Figure 2-6: Principal Component 
Analysis (PC1 versus PC2) according 
to GDM  
Figure 2-7: Principal Component 
Analysis (PC1 versus PC3) according 
to GDM 
Figure 2-6 & Figure 2-7 : Principal Component Analysis according to GDM  
The blue dots represent GDM and the red dots represent no GDM. There were no distinct 
clusters of samples seen between GDM and no GDM. 99.7% of the variance was captured in 
PC1, 0.2% of the variance was captured in PC2 and 0.1% of the variance was captured in PC3. 
 
Figure 2-8: Principal Component 
Analysis (PC2 versus PC3) according to 
GDM 
Figure 2-8: Principal Component Analysis according to GDM 
The blue dots represent GDM and the red dots represent no GDM. There were no distinct 
clusters of samples seen between GDM and no GDM. 0.2% of the variance was captured in 
PC2 and 0.1% of the variance was captured in PC3. 
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A line could not be drawn between GDM and no GDM in any of the plots. 
Hence, supervised learning methods were applied to design and develop a 
GDM predictive model using random forest and decision tree modelling.  
A GDM predictive model was developed using the Random Forest (RF) 
algorithm. RF is an ensemble learning method based on the combination of 
several decision trees in order to provide a more accurate prediction than the 
individual trees on their own [138]. RF was implemented using the 
“randomForest” function from the “randomForest” package [140]. The 
optimisation confusion matrix (Figure 2-9) indicates that for the model achieved 
100% classification accuracy where all 227 training samples were correctly 
classified. The model validation achieved an initial prediction accuracy of 
81.1%; where 61 out of 75 samples where correctly predicted. However, 14 
patients were wrongly classified.  
 
                   
Figure 2-9 : Confusion Matrix for prediction of GDM 
The model achieved 100% classification accuracy where all 227 training samples were correctly 
classified. The validation model predicted 61 testing samples correctly out of 75 giving an initial 
prediction accuracy of 81.1%. 
Upon running a series of 200 iterations, while randomly reshuffling samples 
within the training and testing subsets, the model stabilised after 20 iterations as 
showed from the performance accumulative mean, achieving a mean 
performance of 77.5% (Figure 2-10). 
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Figure 2-10: GDM model performance using Random Forest 
The model‟s performance accumulative mean was 77.5% 
Variable importance for predicting GDM, measured by RF, was measured using 
the “varImpPlot” function. The VFM came as the most important variable, 
followed by BMI, skeletal muscle mass (SMM), weight and PBF in that order. 
Less important variables included waist-Hip ratio, history of previous GDM and 
history of polycystic ovarian syndrome (PCOS) (Figure 2-11). 
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Figure 2-11: Ranking of variables as predictors of GDM 
Visceral fat mass was the most important variable followed by BMI, SMM, weight and 
percentage body fat.  
The decision tree used a value of VFM < 210 as the first split, which was the 
most important split in any decision tree (Figure 2-12).  
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Figure 2-12: Decision tree for predicting GDM 
The decision tree for predicting GDM used VFA < 210 as the first split  
The birth centile is classified into 3 groups in routine clinical practice: birth 
centile <10 as low birth centile (small for gestational age), birth centile between 
10 and 90 as normal birth centile and birth centile > 90 as high birth centile 
(LGA). PCA was carried out as before by reducing the variables into two 
principal components and plotting the variance. There was no distinct clustering 
of samples seen between the three birth centile classes and hence no evident 
separation. 98.9% of the variance was captured in PC1, 0.7% of the variance 
was captured in PC2 and 0.2% of the variance in PC3. However, there was no 
evident separation in both PC1 versus PC2 and PC1 versus PC3 (Figure 2-13 & 
Figure 2-14). 
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Figure 2-13: Principal Component 
Analysis (PC1 versus PC2) according 
to birth centile classes 
Figure 2-14: Principal Component 
Analysis (PC1 versus PC3) according 
to birth centile classes. 
The blue dots represent normal birth centile, the red dots represent high birth centile and the 
green dots represent low birth centiles. 98.9% of the variance was captured in PC1, 0.7% of the 
variance was captured in PC2 and 0.2% of the variance in PC3. 
The analysis is repeated with important variables only, excluding age and 
height. Again, there was no evident separation seen (Figure 2-15 & Figure 
2-16). 
The blue dots represent normal birth centile, the red dots represent high birth centile and the 
green dots represent low birth centiles. There were no distinct clusters of samples seen 
between the classes. 99.7% of the variance was captured in PC1, 0.2% of the variance was 
captured in PC2 and 0.1% of the variance was captured in PC3. 
  
Figure 2-15: Principal Component 
Analysis (PC1 versus PC2) according to 
birth centile class (without age and 
height) 
Figure 2-16: Principal Component 
Analysis (PC1 versus PC3) according 
to birth centile class (without age and 
height) 
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The PCA failed to classify correctly and hence the Random Forest algorithm 
was used. 
Random Forest to predict birth centile classes  
A birth centile predictive model was developed using the RF algorithm on 
similar lines as the development of the GDM predictive model. The input data 
managed to predict birth centile class correctly with an average of 68%.174 out 
of 191 (91.1%) from the normal birth centile class were predicted correctly. In 
the low birth centile class, only 4 were predicted right out of 52 and none of the 
ones from the high birth centile class were predicted right (Figure 2-17). The 
model was well trained in predicting normal birth centile but not so in extremes.  
 
Figure 2-17: Confusion matrix for birth centile classes  
The matrix showed that the model predicted birth centile classes with an average of 68% 
accuracy.174/191 normal birth centiles were predicted correctly.      
 
2.7 Discussion 
The literature search did not reveal any published studies to date that examined 
the possible role of directly measured VFM and its relation to pregnancy 
outcomes in obese women. Therefore, to my knowledge, this was the first study 
examining the role of VFM in obese pregnant women. 
The results showed that VFM in early pregnancy is a novel risk factor for GDM 
[142]. There was a moderately positive correlation of VFM with fasting glucose 
and HbA1c in all patients who developed GDM.  Similar correlations of VFM with 
fasting hyperglycaemia and HbA1c have been shown in patients with T2DM 
[110]. There was a weak correlation between total PBF and fasting glucose but 
no correlation between total PBF and HbA1c. This suggests that non-visceral 
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subcutaneous fat may not have the same metabolic effect as visceral fat. This 
fits in with the proposal  that GDM should be considered as a part of metabolic 
syndrome [143][144]. The study results confirmed a significant association 
between the higher baseline VFM (≥ 75th percentile) and risk of subsequent 
gestational diabetes. Obese women with a VFM ≥ 75 percentile measured in 
early pregnancy have a 3-fold risk of subsequent GDM (Table 2-11). 
In the general population, it is already well-established that excess visceral fat 
and insulin resistance, but not general adiposity, are independently associated 
with pre-diabetes and T2DM in obese adults [107][108]. The results of my study 
suggested a similar association between VFM and risk of GDM in obese 
pregnant women.  
In my study, Asian women who developed GDM have a lower BMI and a 
significantly lower VFM compared with Caucasians. This is in conformity with a 
recently published study by Hedderson et al [145]. This study concluded that  
clinicians should be aware that the BMI thresholds for increased risk of GDM 
varies by racial/ethnic group and that risk is high even at relatively low BMI cut 
offs in Asian and Filipina women. Hence, Asian women may benefit from 
different prevention strategies for GDM in addition to weight management [145]. 
In the Asian cohort of my study, those developing GDM had a higher VFM and 
markers of central obesity. Despite small numbers in this study, these 
observations are in keeping with the suggestion that Asians are particularly 
susceptible to diabetes even at lower BMIs. The pathogenic link between 
visceral fat and onset of diabetes is likely to be through the development of 
insulin resistance. Studies in T2DM have shown that visceral fat accumulation 
decreases insulin sensitivity and has a negative impact on glycaemic control 
[110]. Visceral adipocytes are known to release a variety of inflammatory 
cytokines such as interleukin 1 and 6, tumour necrosis factor and resistin which 
have been suggested to induce insulin resistance.  I did not measure cytokines 
or any of the inflammatory markers in this study, which is one of the limitations 
of the study. 
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There is an increased risk of fetal macrosomia in pregnancies complicated by 
GDM and obesity. I found no significant difference between the neonatal birth 
weights and other neonatal outcomes in the two groups, which possibly again 
was a reflection of the intensive management of GDM in these women (Table 2-
7).  
According to the decision tree developed, VFM emerged as the most important 
variable in determining the risk of GDM, followed by BMI, SMM, weight, and 
PBF and waist hip ratio. Factors like previous GDM, history of polycystic ovarian 
syndrome, family history of diabetes and previous macrosomia were less 
important variables (Figure 2-11).These results add to the growing evidence of 
the importance of central obesity and in particular, VFM in the development of 
GDM. The decision tree used a value of VFM < 210 as the first spilt which was 
the most important split in the decision tree. 
The model managed to predict GDM with an average prediction accuracy of 
77.5%, which is an overall good performance. However, even though it gave a 
good performance in predicting no-GDM, two-thirds of the true GDMs were 
wrongly classified. This is largely due to the unbalanced distribution of both 
classes of patients, as only 24% of patients in the original dataset developed 
GDM. Hence, the model shows a bias in prediction towards the no GDM class.  
[146]. Similarly, with the birth centile model, it correctly predicted birth centile 
classes with an average of 68%. The model was well trained in predicting 
normal birth centile but not as accurate in predicting low or high birth centile. 
Hence the prediction of the birth centile model showed a slight bias towards the 
normal birth centile class. Studies have shown us that GDM alone predicts 
macrosomia poorly and hence the birth centile model would be very useful [74] 
[76] [92]. 
This was probably the first attempt to create a mathematical model to predict 
GDM and LGA baby using VFM in addition to classical risk factors. Measuring 
the VFM with the InBody 720 is a simple and non-expensive test which can 
easily be done in a clinical setting. The clinical significance of this study is the 
potential for early and personalised risk stratification for GDM allowing low risk 
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obese women to avoid unnecessary diagnostic testing, additional clinic visits 
and growth scans. Conversely those at high risk can start dietary and lifestyle 
interventions early to reduce the risk of complications. 
The strengths of this study include direct measurement of fat distribution in vivo 
in early pregnancy in ambulant women attending a single centre with 
standardised dietary and exercise advice. A range of clinically relevant and 
novel predictors of GDM were simultaneously measured rather than one novel 
factor measured in isolation. As such, the model created had greater validity. A 
limitation of the study is that there was no comparison with a cohort of non-
obese women. Also, ethnicity was not included in the model as our dataset 
contained predominantly Caucasian women. Another limitation was that insulin 
sensitivity was not measured in this study. The recommendation is to design a 
clinical study with a larger number of pregnant women, across the BMI 
spectrum in order to confirm the findings, train the model better and improve its 
accuracy. One study showed  that obesity in a multi-ethnic population cannot be 
defined by a single set of new cut points for BMI, but varied cut offs depending 
on the outcome assessed [47].   
  
2.8 Conclusions 
This study showed that visceral fat mass is a novel risk factor for the 
development of GDM in obese pregnant women. Obese pregnant women with 
VFM ≥ 75th percentile have a 3-fold higher risk of developing GDM. A 
mathematical model was developed with good overall performance in predicting 
gestational diabetes and LGA babies in obese pregnant women early in 
pregnancy. The model will require further training with data from a larger cohort 
of obese pregnant women to confirm the findings and improve its performance 
so that it can be adopted as a clinical tool in the management of obese 
pregnant women. 
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3     METFORMIN IN OBESE NON-DIABETIC PREGNANT 
WOMEN (MOP) TRIAL 
 
This chapter begins with an outline of the complications of obesity in pregnancy 
and a description of the aims and objectives of the “Metformin in obese non-
diabetic pregnant women trial (MOP Trial)”. Lifestyle intervention programmes 
in pregnancy have shown some benefits on maternal outcomes such as GWG 
but no evidence of benefits for the neonate [113][147][148][149]. Therefore, the 
MOP trial, which investigated the possible beneficial effects of metformin in 
obese pregnant women, fulfilled an unmet need in a timely manner. This 
chapter goes on to describe the methodology and results of the MOP trial.     
3.1 Introduction 
The proportion of women with obesity in the UK is a matter of concern. The 
Health Survey of England 2013 reported that approximately 1 in 4 women were 
obese and 2 out of 3 women had a high or very high waist circumference [150]. 
The CMACE [69] reported that nearly 5% of pregnant women in UK had a BMI 
of > 35 kg/m2. The literature review showed that obesity is associated with a 
number of serious adverse outcomes including gestational diabetes and 
preeclampsia [68][151]. Being overweight or obese contributes to over half of 
maternal mortality [69]. Obesity during pregnancy is associated with an 
increased risk of adverse short-term and long-term consequences for both 
mother and baby [131]. Excessive weight gain in pregnancy is also associated 
with an increased risk of complications [71].  
As lifestyle intervention programmes in pregnancy have shown no evidence of 
benefits for the neonate, investigators have turned to pharmacological 
interventions and, in particular the insulin-sensitising agent metformin [113] 
[147][148]. Since insulin resistance is increased in obesity and is strongly 
associated with birth weight and fetal adiposity [131], metformin is a rational 
choice to improve outcomes in this population.  Metformin primarily acts on the 
liver but also affects skeletal muscle, adipose tissue, endothelium and ovaries. 
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It reduces fasting serum insulin by 40% and leads to weight reduction by 5.8% 
[133]. It improves insulin sensitivity, reduces hepatic gluconeogenesis and 
increases peripheral glucose uptake [41]. Metformin is eliminated by the kidney 
and has increased clearance in pregnancy [130].  
Because it crosses the placenta, there have been concerns about its safety in 
pregnancy. Data from its use in pregnancy in obese women with polycystic 
ovarian syndrome has shown it to be safe with no evidence of teratogenicity 
[42]. Metformin is currently classified as a Category B drug for use during 
pregnancy. The NICE has recommended metformin as first-line therapy for 
gestational diabetes when dietary intervention fails to control the blood glucose 
[125].      
The Metformin in GDM (MiG) study [40] concluded that in women with GDM, 
metformin (alone or with supplemental insulin) is not associated with increased 
perinatal complications as compared with insulin. GWG was significantly lower 
in the metformin treated women although there were no differences in birth 
weight between the groups. In my previous work, done as part of the St Helier 
diabetes team, I showed that women with GDM treated with metformin showed 
a 20% birth weight centile reduction and lesser number of LGA babies versus 
insulin treated women. Also, women in the metformin group gained significantly 
less weight in pregnancy [152]. A small study in women with polycystic ovaries 
showed that metformin during pregnancy reduces insulin, insulin resistance and 
development of gestational diabetes [133]. Outside of pregnancy, the Diabetes 
Prevention Program research group showed that metformin reduced the 
incidence of T2DM in patients with impaired glucose tolerance by 31% [153].  
 
3.2 Rationale 
Based on the literature review, there is substantial evidence that obesity in 
pregnancy contributes to increased morbidity and mortality for both mother and 
baby [67].The important complications associated with obesity in pregnancy are 
an increased risk of GDM, pregnancy induced hypertension, preeclampsia, 
thromboembolic complications and LGA babies [68]. Lifestyle intervention 
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programmes have shown no benefit for the neonate [112][148][149]. Research 
studies and new interventions which could decrease the incidence and severity 
of complications for both mother and baby are therefore very important and 
make this study very timely. 
Pregnancy is an insulin resistant state and more so, in obese women. 
Metformin inhibits gluconeogenesis and reduces free fatty acid levels and 
thereby improves insulin sensitivity [40]. It also stimulates Glucagon-like-peptide 
1 (GLP-1) release and insulin secretion. Weight loss has been observed during 
metformin treatment. Metformin has been classified as a Class B1 drug in 
pregnancy. It crosses the placenta but there is no evidence of adverse fetal 
effects [40]. Limited or no weight gain during pregnancy in obese pregnant 
women is associated with a significantly lower risk of PET, CS and LGA and a 
more favourable pregnancy outcome [88].  
Several small studies suggest that metformin could be beneficial in pregnancy 
due to its insulin sensitizing action, thereby reducing the risk of GDM and 
incidence of LGA babies [133][154].  It may also decrease the risk of pregnancy 
induced hypertension and preeclampsia [155]. Thus, treatment with metformin 
from the beginning of the 2nd trimester may improve the overall pregnancy and 
neonatal outcomes in obese non-diabetic pregnant women. It is further 
hypothesised that metformin may be more effective in a subgroup of obese 
pregnant women having high baseline insulin resistance and treatment of this 
selective subgroup of women with metformin may reduce the risk of GDM. 
 
3.3 Aims of the study 
1. To investigate whether metformin improves pregnancy outcomes (incidence 
of LGA (≥90% birth weight centile) babies, onset of maternal GDM, 
hypertension, preeclampsia, macrosomia, shoulder dystocia, admission to 
SCBU in obese non-diabetic women. 
We aim to compare perinatal outcomes in women randomised to the two groups 
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                Group 1: Standarised life style intervention and placebo 
                Group 2: Standarised life style intervention and metformin 
2. To determine whether there is an association between baseline insulin 
resistance and adverse pregnancy outcomes such as gestational diabetes, 
pregnancy-induced hypertension and preeclampsia. 
3. To investigate whether metformin will improve body fat distribution with 
particular emphasis on VFM during pregnancy          
4.  To examine the hypothesis that metformin is most effective in those patients 
with the highest baseline insulin resistance and treatment with metformin 
throughout pregnancy will reduce the risk of gestational diabetes in this group of 
women. 
 
3.4  Objectives of the study 
1. To set up a randomised controlled trial in obese non-diabetic pregnant 
women with BMI ≥ 35 kg/m2. 
2. To obtain ethical approval and Clinical Trial Authorisation from Medicines 
and Health Regulatory Agency (MHRA). 
3. To organise manufacture and packaging of placebo to match the 
metformin. 
4. To obtain informed written consent of each participant. 
5. To randomise recruited women to metformin or placebo. 
6. To organise Oral glucose tolerance test (OGTT), fasting insulin and other 
blood tests at recruitment. 
7. To measure the body composition of women at recruitment and repeat at 
22 weeks, 28 weeks, 36 weeks and postnatal. 
8. To record the results of the OGTT conducted at 28 weeks of gestation. 
9. To record all adverse events in the participants. 
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10. To perform statistical analysis and compare the baseline characteristics, 
body composition, pregnancy and neonatal outcomes between the 
women randomised to metformin or placebo.  
11. To calculate insulin resistance at booking and 28 weeks of gestation 
using the Homeostatic model assessment (HOMA) model. 
12. To perform statistical analysis to compare the change of fasting insulin, 
insulin resistance, visceral fat and CRP at 28 weeks of gestation from 
baseline in the metformin and placebo groups. 
 
3.5  Material and Methods 
3.5.1 Ethical approval 
I obtained the ethical approval from the London-Surrey Borders Research 
Ethics committee (REC no 08/H0806/80) (EudraCT no. 2008-005892-83) on 
19th November 2008 (Appendix B.1). I obtained the Clinical Trial Authorisation 
(CTA) from the MHRA on 14th January 2009 (Appendix C.1). I registered the 
trial at clinicaltrials.gov (NCT01273584). I also obtained the Cranfield University 
Health Research Ethics Committee (CUHREC) approval on 05-07-2013 (Project 
Reference No. 24/13) (Appendix D.1).  
I informed the subject‟s general practitioner of the intention to enrol a subject 
into the study. No study specific procedures was undertaken on any subject 
until that subject gave written informed consent. The study was conducted in 
accordance with the principles of Good Clinical Practice. 
 
3.5.2 Inclusion Criteria 
1. Obese pregnant women with BMI ≥ 35 kg/m2 
2. Gestation between 12 and 16 weeks 
3. Age greater than 18 years. 
4. Informed written consent 
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3.5.3  Exclusion Criteria 
1. Pre-existing known diabetes or previous gestational diabetes 
2. Presence of contra-indication to metformin (renal, liver, heart failure) 
3. Moving out of study area for pregnancy management 
4. Participants who suffer with hyperemesis 
5. Multiple Pregnancy 
6. Known sensitivity to metformin or its excipients 
 
3.5.4 Study design 
It was a randomised, prospective, double-masked, placebo controlled trial   
conducted at St Helier Hospital and 2 other NHS hospitals in the UK. All women 
attending the antenatal obesity clinic and fulfilling the eligibility criteria were 
invited to take part in the MOP trial. I discussed the trial with the prospective 
participants in detail, and gave a participant information sheet to patients who 
expressed an interest. 378 obese pregnant women were screened for eligibility. 
The women were given at least 24 hours to confirm participation. All women 
who agreed to participate in the trial provided written informed consent. 93 
women were excluded due to various reasons like established diabetes or other 
systemic illness. All women received standardised personal advice on healthy 
eating and carbohydrate content of food, emphasizing low glycaemic index 
foods.  
133 women attending the antenatal obesity clinic at the St Helier Hospital and 
fulfilling the eligibility criteria consented to take part in the study. Of these, 118 
women completed the study. These 118 women recruited at St Helier Hospital 
formed the cohort for my study (Figure 3-1).  
Before randomisation, I recorded the demographics, medical and obstetric 
history for each participant. Participants had baseline blood tests including 
OGTT, HbA1c, fasting insulin and CRP measurements. I performed the body 
composition analysis by bioelectrical impedance using InBodyTM720 at baseline 
on all participants and repeated it at each visit. 
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Figure 3-1: Flowchart for women participating in the MOP Trial 
The flowchart shows that 133 obese pregnant women consented to the MOP trial and 
randomised 1:1 to metformin or placebo. 
Randomisation and Trial medications 
Eligible women were randomised in a 1:1 ratio to either active treatment with 
metformin or to placebo. The randomisation was computer generated by a 
statistician. The implementation of the random allocation sequence was carried 
out by the local pharmacist at the site, using sequentially numbered containers.  
Obese pregnant women (BMI ≥ 35kg/m2)              
N=378 
N=133 obese pregnant women consented                               
Randomised 1:1 to metformin and placebo                         
(14 withdrew consent + 1 was withdrawn) 
Exclude: established diabetes, previous GDM, 
other systemic illness (n=93) 
Maternal measurements during pregnancy and 
postpartum                                                         
Primary outcome- Birth weight z score 
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Both the participants and the clinical research team were blinded to the type of 
intervention. .  
Composition of the placebo 
The placebo tablets were manufactured to look identical to the metformin 
tablets by University College of London (UCL) Hospitals NHS Foundation Trust 
(Manufacturers License Number MIA (IMP) 17022).  
The composition of the placebo tablets was  
Lactose Ph Eur                                                         84.25% w/w 
Microcrystalline cellulose  (Avicel ® PH 102)              15.00 w/w 
Magnesium Stearate BP                                           0.75% 
The UCL Hospitals pharmacy was also the central randomisation facility. 
Women in both groups were prescribed metformin/placebo on their first visit 
after randomisation. All women received standardised personal advice on 
healthy eating, emphasizing low glycaemic index foods, and were encouraged 
to undertake 30 minutes of physical activity daily.  
Clinical Assessments  
The schedule of clinical assessments is shown in Table 3-1. 
Clinicians performing these assessments were blinded to treatment allocation. I 
saw all participants at 4-6 week intervals and assessed them clinically including 
weight, blood pressure, maternal assessment. Fetal assessment was done by a 
midwife. All women had their urine tested & recorded for proteins and ketones 
at every visit. I recorded the clinical data of the participants at each antenatal 
visit, delivery and neonatal outcomes for each participant. I monitored and 
recorded subject compliance with trial medications with history and tablet 
counts at each antenatal visit. I recorded the details of adverse events, if any, 
for each participant throughout the pregnancy. I also recorded overnight 
admissions to hospitals, if any in the case record forms.  
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Table 3-1 Schedule of visits for participants of the MOP Trial 
All obese pregnant women with BMI ≥ 35kg/m
2
 were screened for eligibility to participate in the 
trial. Inclusion and exclusion criteria were applied.  
Visit No 
 
 
1 
Screening 
BMI>35 
2 
Recruit 
3 4 5 6 7 8 
Week of gestation 10-12 12-16 20-22 26-28 32-34 36-38 Delivery/ 
Neonatal 
Postna
tal 
 Inclusion/ 
Exclusion  
X        
Informed Consent  X 
 
      
Randomisation to 
Metformin/ Placebo 
 Ҳ       
 Medical and 
obstetric History 
X Ҳ       
 
Blood Pressure, 
Urine, 
fetal check 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
Body Composition X X X X X X  X 
OGTT  X 
 
 X    X 
GDM+ 
Fasting Insulin  Ҳ  Ҳ 
 
    
CRP, 
 HbA1c 
 Ҳ 
Ҳ 
Ҳ Ҳ  Ҳ  
 
 
Adverse Event   Ҳ Ҳ Ҳ Ҳ X 
 
 
Dispensing of  
Placebo/ Metformin  
 Ҳ Ҳ Ҳ Ҳ Ҳ   
Delivery and baby 
details 
      X 
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The dosing schedule of the trial medications is 500 mg twice a day in week 1 
and thrice a day in week 2. In week 3, this was gradually increased to 1000 mg 
with breakfast and 500 mg with lunch and dinner. In week 4, the dose was 
further increased to 1000 mg with breakfast and dinner and 500 mg with lunch. 
Finally, in week 5, the women reached the maximum dose of 1000 mg of the 
trial medications with each meal and this dose was continued till the delivery of 
the baby.  
I advised women to take metformin during meals to reduce the risk of 
gastrointestinal side-effects. In women unable to tolerate the full dose, the 
maximum  tolerated dose was continued till the birth of the baby. I recorded this 
reduced dose in the case record form and created an adverse event form. 
Unblinding of treatment allocation was only permitted on the recommendation of 
the Data Safety Monitoring Committee where knowledge of the treatment was 
necessary for clinical reasons or for management of an adverse event.  
I advised participants not to take metformin within 48 hours of having a general 
anaesthetic. If participants were to undergo an emergency operation, I would 
ensure that the anaesthetist was informed that they have been taking 
metformin. 
I performed body composition analysis on all participants using the 
InBodyTM720 body composition analyser at booking and at each visit including 
the postnatal visit. The InBodyTM720 performed body composition analysis 
using Direct Segmental Multi-frequency Bioelectrical Impedance Analysis 
Method (DSM- BIA Method). I saw all women at 6-8 weeks postpartum and 
recorded their weight, blood pressure and general well-being. In patients who 
developed GDM, the OGTT was repeated postnatal to screen for persistent 
glucose intolerance or type 2 diabetes.  
Blood Tests 
All recruited women had blood tests at recruitment, 22 weeks, 28 weeks and 36 
weeks of gestation. An OGTT and a baseline HbA1c was performed in all 
women soon after randomisation. The results of this test were masked to 
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patients and clinicians. All women had a second OGTT at 28 weeks of gestation 
in line with standard practice for screening for GDM at St Helier Hospital. Trial 
medications were stopped for 1 week prior to the date of the test so as to 
exclude any influence on the OGTT results. The WHO 1999 criteria for 
diagnosis of GDM were used.  
All women had fasting glucose and insulin measurements at baseline in order to 
assess insulin sensitivity. The serum was separated and frozen at -20o C and 
stored for analysis of fasting insulin. Samples were batched and analysed 
together to avoid inter-assay error. In a subset of 43 patients, fasting insulin 
levels was repeated at 28 weeks to assess changes in insulin resistance. 
Insulin was measured by radioimmunoassay at the SAS Peptides Hormone 
Section, Royal Surrey County Hospital, UK with the Mercodia Iso-Insulin ELISA 
kit and I participated in these measurements. This is a solid phase two-site 
enzyme immunoassay. It is based on the direct sandwich technique in which 
two monoclonal antibodies are directed against separate antigenic determinants 
on the insulin molecule. During incubation, insulin in the sample reacts with 
peroxidase-conjugated anti-insulin antibodies and anti-insulin antibodies bound 
to the micro-titration well. A simple washing step removes unbound enzyme 
labelled antibody. The bound conjugate is detected by reaction with tetra methyl 
benzidine. The reaction is stopped by adding Sulphuric acid to give a 
colorimetric endpoint that is read spectrophotometrically. The lower limit of 
detection in this kit is 1mU/L. The intra-assay and inter-assay coefficient of 
variation at a concentration of 15.9 mU/L were 3% and 3.9% respectively. 
I referred the women with abnormal results on the OGTT to a joint antenatal 
specialist diabetes clinic. They were given specialist advice by a dietitian and 
were taught home glucose monitoring. They were advised to continue the study 
medication and to continue home glucose monitoring till birth of the baby. If 
target blood glucose values are not achieved on dietary modifications, insulin 
was added to the study medications. Women with normal OGTT results 
continued with the trial medications as before. I reviewed the home glucose 
readings at periodic intervals throughout the pregnancy (Figure 3-2).  
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Figure 3-2: Flow chart for women who developed GDM  
All women who developed GDM were referred to the antenatal diabetes clinic. They were seen 
by the dietitian and asked to start home glucose monitoring. If adequate glucose control was 
achieved, women continued trial medications as before. If glucose control was inadequate, 
insulin was added in addition to the trial medications. 
I used the Homeostatic model assessment (HOMA) as a surrogate marker of 
insulin resistance. The HOMA model is derived from a mathematical 
assessment of the interaction between β cell function and insulin resistance in 
an idealised model that is then used to compute steady state insulin and 
glucose concentrations. The output of the model is calibrated to give normal 
beta cell function of 100% and normal insulin resistance of 1. The relationship 
between glucose and insulin in the basal state reflects the balance between 
hepatic glucose output and insulin secretion, which is maintained by a feedback 
loop between the liver and the β cells [156]. The hyperinsulinaemic-euglycaemic 
clamp method is the gold standard to measure insulin sensitivity but it is an 
expensive and time consuming. Hence I used HOMA-IR as a surrogate 
estimation of insulin sensitivity, based on fasting glucose and insulin. It 
correlates well with the clamp method [156]. However, HOMA is based on 
Women with positive OGTT at 
28 weeks gestation 
Referred to antenatal diabetes clinic 
Adequate glucose control 
Continued trial medications 
Inadequate glucose control 
Continued trial medications 
and insulin added 
Commenced home glucose monitoring, dietitian input, continued trial medication 
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fasting glucose and insulin concentrations and GDM, at least to begin with, is a 
postprandial disease and this needs to be considered.  I calculated HOMA-IR 
using the following equation (Equation 3-1). 
Equation 3-1: HOMA-IR 
 
 
 
Ultrasound Scans 
All women participating in the study were scanned at 30 and 34 weeks of 
gestation to assess fetal growth. Additional growth scans were performed in 
those who develop GDM in line with the standard clinic protocol for GDM at St 
Helier Hospital. 
Adverse events 
Patients were advised to contact me or the midwife in the event of any new 
symptoms. I recorded any adverse event in the patient‟s notes and in the case 
record. Details recorded include the nature of the event, time of onset, severity, 
treatment needed and any relation to the trial medication. I reported all serious 
adverse events (SAE) to the sponsor immediately. Hospitalisation for the 
following reasons was not considered as Serious Adverse Events in this study. 
1. Irregular uterine contractions requiring observation for < 24 hours. 
2. Vaginal bleeding requiring observation for < 24 hours. 
3. Show or Spontaneous Rupture of membranes 
Any admission to the hospital during the pregnancy for greater than 24 hours 
was considered as a SAE. 
Withdrawal of subjects 
An obese pregnant women participating in the study was withdrawn from the 
study, if her fetal growth scan showed:                                                       
Estimated fetal weight (efw) < 5th centile                                                                
HOMA-IR = Fasting Insulin (microU/L) x Fasting glucose (mmol/L) 
                                                      22.5 
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and                                                                                                                   
Either reduced end diastolic flow in the umbilical artery or                                                                                                        
Oligohydramnios defined as amniotic fluid index < 2cm 
Outcome measures 
Primary outcome 
The primary outcome measure was the median neonatal birth-weight z score 
(difference between observed and expected birth weight, with adjustment for 
gestational age, divided by the fitted standard deviation). The expected birth 
weight, corrected for gestational age, was derived from the local population of 
phenotypically normal neonates born alive at 24 weeks of gestation or later. 
[157].   
Secondary outcomes 
Maternal secondary outcome measures included maternal gestational weight 
gain (defined as the difference in maternal weight between the last antenatal 
visit and the day of randomisation), GDM, preeclampsia, pregnancy induced 
hypertension, delivery by Caesarean section, and postpartum haemorrhage, 
defined as blood loss of 1 litre or more. 
Secondary neonatal outcomes included miscarriage at less than 24 weeks of 
gestation, stillbirth at 24 weeks or more, preterm birth at less than 37 weeks, a 
LGA neonate (birth weight > 90th percentile adjusted for gestational age), birth 
trauma (shoulder dystocia, brachial plexus injury or fracture), Apgar score < 7 at 
5 minutes, admission to level 2 or 3 neonatal unit, hypoglycaemia (plasma 
glucose levels < 2.6 mmol/l on two occasions at greater than 30 minutes apart), 
hyperbilirubinemia requiring phototherapy and respiratory distress defined as 
the need for more than four hours of respiratory support or oxygen. 
3.5.5 Statistical Analysis 
I performed the statistical analysis using R. Each continuous variable was 
tested individually for normality using the skewness and kurtosis test. The 
normally distributed data have been expressed as mean ± standard deviation.  
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Welch‟s t-test or Independent two samples t-test which is a parametric test was 
used to compare the means of two groups. Fisher‟s test was used to compare 
categorical variables and the level of significance was P<0.05. The association 
between variables in a normally distributed data was investigated with the 
Pearson‟s correlation coefficient. 
Data which was not normally distributed has been expressed as median and 
interquartile range. The Mann-Whitney U test, which is a non-parametric test 
was used to explore the difference between the variables in the two groups with 
and without GDM and the level of significance was P<0.05. The association 
between variables in a data not normally distributed was investigated with the 
Spearman‟s rank correlation. Chi-square test or Fisher‟s test was used to 
compare categorical variables and the level of significance is P<0.05. 
3.6 Results 
The study period was October 2010-June 2015 at the St Helier University 
Hospitals NHS Trust.  I assessed a total of 378 obese pregnant women without 
diabetes and with a BMI ≥ 35 kg/m2 and a singleton pregnancy for eligibility. 93 
women were excluded for various reasons like established diabetes, previous 
GDM or other systemic illnesses. In the 285 eligible women, 133 women 
(46.6%) agreed to participate in the study. The obese women tend to attend 
their first antenatal visit later than normal weight women, but in spite of that, I 
managed to recruit women between 12 and 16 weeks of gestation. After 
randomisation 14 women withdrew their consent, 6 in the metformin group and 
8 in the placebo group. In one of the patients, the results of the OGTT were 
inadvertently unblinded. This was a positive test and therefore the patient was 
excluded from the trial for ethical reasons. The remaining 118 women who 
completed the study formed the cohort of my study (Figure 3-1). 
Data distribution 
At the outset, I analysed the distribution of the continuous variables by 
performing the skewness test (Table 3-2). 
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Table 3-2: Tests of normality for maternal and neonatal characteristics 
Variable Minimum Quartile
1 
Median Mean Quartile       
3       
Maximum Skew Norma
lity 
Age (years) 21 29.2 33 32.5 36 43 -0 Yes 
Weight at 
recruitment (kg) 75.7 96.5 104.9 107.7 114.7 170.5 1 Yes 
HbA1c at 
recruitment 
(mmol/l) 
26 32 34 34.3 36 47 0.3 Yes 
BMI at 
recruitment 
(kg/m
2
) 
34.1 36.7 38.9 40.4 42.7 62.1 1.6 No 
Waist Hip Ratio 
at recruitment 0.92 0.98 1.0 1.01 1.04 1.5 3.06 No 
Systolic BP at 
recruitment (mm 
of Hg) 
80 110 117 117.1 123.3 158 0.3 Yes 
Diastolic BP at 
recruitment (mm 
of Hg) 
55 70 77 75.9 83 100 -0.3 Yes 
Visceral fat 
mass at 
recruitment 
(units) 
136.3 166.8 188 197.5 222.8 374.7 1.5 No 
OGTT-1 
Fasting BG 
(mmol/l) 
3.7 4.2 4.5 4.5 4.8 6.4 0.7 Yes 
OGTT-1 
2-hour BG 
(mmol/l) 
2.7 4.8 5.9 5.6 6.4 8.4 -0.2 Yes 
OGTT-2 
Fasting BG 
(mmol/l) 
4.6 4.3 4.4 4.5 4.2 4.8 1.4 No 
OGTT-2 
2-hour BG 
(mmol/l) 
3.4 4.8 5.6 5.8 6.9 10.0 0.6 Yes 
Fasting insulin 
at recruitment 
pmol/l  
24 73 94 105 133 253 0.9 Yes 
HOMA-IR at 
recruitment 
(score) 
0.42 1.29 1.68 1.88 2.39 4.5 0.9 Yes 
CRP at 
recruitment 
(mg/l) 
2.1 7.6 11.2 13.2 17.1 48.7 1.6 No 
Fasting insulin 
at 28 weeks 
(pmol/l) 
4.5 76.2 116 125 157 448 2.1 No 
HOMA-IR at 28 
weeks (score) 0.56 1.42 2.09 2.31 2.71 6.9 1.64 No 
CRP at 28 
weeks (mg/l) 1.3 5.9 10.4 13.0 16.7 53.9 1.6 No 
VFM at term 
(units) 143.2 179.8 200.5 207.7 231.4 343.8 1.1 No 
VFM postnatal 
(units) 125.6 163.6 183.3 192.6 216.7 354.2 1.4 No 
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Birth weight 
(grams) 
1100 3141 3500 3494 3882 5040 -0.66 Yes 
Some of the variables have a normal distribution while others have a non-normal distribution 
Baseline characteristics 
Among the 118 women who completed the study, 59 women were randomised 
to metformin and 59 to placebo at recruitment. Women allocated to metformin 
or placebos were similar in age, booking weight, BMI and baseline fasting and 
2-hour glucose values during OGTT (Table 3-3). 
Table 3-3: Maternal baseline data: metformin and placebo groups 
 
a 
Independent two samples t-test, 
b 
Mann-Whitney U test, IQR-interquartile range. There was no 
significant difference between the maternal baseline characteristics between the metformin and 
placebo groups. 
The ethnic distribution of women was not different between the groups. In the 
metformin group, 79.7% of the women were Caucasians, 11.9% were Asians 
and 8.4% Blacks. In the placebo group, 77.9% were Caucasians, 10.2% Asians 
and 11.9% Blacks (Table 3-4).The number of women with polycystic ovarian 
syndrome and hypertension were similar in both groups. There was no 
significant difference in the number of smokers in the metformin or the placebo 
group (P=0.7) 
 
 
Metformin group  
n=59 
Mean (± SD) a 
Median (IQR)b 
 
Placebo group 
n=59 
Mean (± SD) a 
Median (IQR)b 
P value 
 
Age (years) 
33.3 (± 4.9) 32 (± 5.3) 0.2a 
Weight (kg) 
106.8 (± 15.5) 109.7 (± 18.2) 0.4a 
BMI (kg/m2) 
39.4 (36.7-42.5) 38.1 (36.8-43.4) 0.8b 
Baseline OGTT- 
fasting BG, mmo/l 
4.5 (± 0.7) 4.6 (± 0.7) 0.4a 
   Baseline OGTT- 
   2-hour BG, mmol/l 
5.7 (± 1.4) 5.5 (± 1.3) 0.4a 
HbA1c ,mmol/mol 
34.2 (± 10.9) 34.5 (± 7.2) 0.9a 
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Table 3-4: Maternal baseline characteristics: Statistical comparison between the 
metformin and placebo groups. 
 
 
 
Metformin group  
(n=59) 
 
Placebo group 
 (n=59) 
 
P value a 
Ethnicity n (%) 
Caucasians 
Asians                                                                                        
Blacks 
 
47 (79.7) 
7 (11.9)
5 (8.4) 
 
 
46 (77.9) 
6 (10.2) 
7 (11.9) 
 
0.82 
0.77 
0.8 
 
History of Polycystic ovarian 
syndrome, n (%) 
 
13 (22) 
 
11 (18.6) 
 
0.8 
Hypertension, n (%) 7 (11.9) 5 (8.4) 0.8 
Cigarette Smoking, n (%) 
 
3 (5.1) 5 (8.5) 0.7 
a 
Fisher‟s exact test. There was no between-groups difference in the ethnic distribution. There 
are no significant differences in number of women with history of polycystic ovarian syndrome 
and hypertension between the two groups.  
The OGTT results showed, similar median fasting glucose (4.6 mmol/l (4.3-4.9) 
vs. 4.6 mmol/l (4.4-5.1), P=0.4) and similar mean 2-hour glucose values (5.9 ± 
1.6 mmol/l vs. 5.8 ± 1.9 mmol/l, P=0.8) in women who received metformin or 
placebo (Table 3-5). 
Table 3-5: 28-week Oral Glucose Tolerance Test results 
 
a
 Independent two samples t-test, 
b 
Mann-Whitney U test, IQR- interquartile range. There is no 
significant difference between the fasting and 2-hour glucose values between the metformin and 
placebo groups.  
 
Metformin  n=59 
Mean (± SD) a 
Median (IQR) b 
Placebo  n=59 
Mean (± SD) a 
Median (IQR) b 
P 
Value 
OGTT-fasting glucose 
(mmol/l) 
4.6 (4.3-4.9) 4.6 (4.4-5.1) 0.4 
OGTT- 2-hour glucose  
(mmol/l) 
5.9 (±1.6) 5.8 (±1.9) 0.8 
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Figure 3-3: Fasting and 2-hour glucose values in the metformin and placebo 
groups at 28 weeks 
MF-F – Fasting glucose in the metformin group, MF-2 hr – 2 hour glucose in the metformin 
group, Pl-F – Fasting glucose in the placebo group, Pl-2 hr – 2 hour glucose in the placebo 
group. 
At baseline, women in the two study groups had similar BMI, WHR, PBF and 
visceral fat mass (Table 3-6). Those allocated to metformin had considerably 
less weight gain during pregnancy (3.9 ± 4.6kg vs. 7.0 ± 4.5 kg, P=0.0003). 
There was a trend for women in the metformin group to have a lower median 
visceral fat at term as compared to the placebo group (199 units [180-229 units] 
vs. 202 units [180-230 units], P=0.97) (Table 3-6). A similar trend was also seen 
at 6 weeks postnatal (181.8 units [155-219 units] vs. 185.8 units [168-213 units], 
P=0.4). However, this difference is not statistically significant 
0
2
4
6
8
10
12
1 11 21 31 41 51
B
l
o
o
d
 
G
l
u
c
o
s
e
 
 Participants 
OGTT values at 28 weeks 
MF-F
MF-2 hr
Pl-F
Pl-2 hr
 90 
Table 3-6: Changes in maternal body composition at 28 weeks- statistical 
comparison between the metformin and placebo groups 
a
 Independent two samples t-test 
   b 
Mann-Whitney U test, IQR-interquartile range. There was 
no significant difference in baseline BMI, WHR, VFM and PBF between the metformin and 
placebo groups. There was also no significant difference in the VFM at term and postnatal 
between the two groups. However, the GWG was significantly lower in the metformin group was 
compared to the placebo group. 
 Metformin group                                             
n=59                       
Mean (± SD) a        
Median (IQR) b 
 
Placebo group
n=59 
 Mean (± SD) a 
Median (IQR) b 
P value 
Baseline Body 
Mass Index (kg/m2) 
 
39.4 (36.7-42.5) 38.1 (36.8-43.4) 0.8b 
Baseline Waist-Hip 
ratio 
 
1.01 (0.99-1.04) 0.99 (0.96-1.04) 0.09b 
Baseline Visceral 
fat mass (units) 
 
      189.2 (171-226) 186.8 (164.8-211.9) 0.4b 
Baseline total 
percentage body fat 
 
49.9  3.3 48.9  4.07 0.2
a 
Visceral fat mass at 
term (units) 
 
198.8 (179.8-229.1) 201.5 (180.4-229.6) 0.97b 
Visceral fat mass 
Postnatal (units)        
181.8 (154.5-218.8) 185.8 (167.9-213.1) 0.4b 
Gestational Weight 
Gain (kg), 
3.9 ± 4.6 7 ± 4.5 <0.05a 
 91 
 
Figure 3-4: Visceral fat mass at recruitment and 36 weeks in the metformin and 
placebo groups 
MF-VFM-R - VFM in the metformin group at recruitment, MF-VFM-36 - VFM in the metformin 
group at 36 weeks, Pl-VFM-R - VFM in the placebo group at recruitment, Pl-VFM-36 - VFM in 
the placebo group at 36 weeks. A trend is seen for women in the metformin group to have a 
lesser increase in visceral fat mass at term. 
At baseline, women in the two study groups had similar fasting insulin levels, 
HOMA- IR scores and CRP levels (Table 3-7). We could only repeat the fasting 
insulin measurements in a small subset of patients (25 patients on metformin 
and 18 patients on placebo) due to financial constraints. Those allocated to 
metformin showed lower fasting insulin at 28 weeks compared to placebo (95 
pmol/l [71-121] vs. 158.5 pmol/l [102.8-195], P=0.009). Similarly, those 
allocated to metformin also showed lower HOMA-IR score at 28 weeks 
compared to placebo (1.98 score [1.29-2.2] vs. 2.81 score [1.92- 3.72], P=0). 
There was a trend towards a lower CRP at 28 weeks in the metformin group as 
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compared to the placebo group.  (9.4 mg/l [5.6-14.4] vs. 11.7 mg/l [7.4-21.9], 
P=0.1). However, the difference was not significant. 
Table 3-7: Changes in fasting insulin, insulin resistance and C-reactive protein at 
28 weeks- statistical comparison between the metformin and placebo groups 
 
a
 Independent two samples t-test,
 b 
Mann-Whitney U test, IQR- interquartile range. The baseline 
fasting insulin, insulin resistance and C-reactive protein were not significantly different in the two 
groups. There was a significant rise in the fasting insulin and insulin resistance at 28 weeks in 
the placebo group as compared to the metformin group. The rise in the CRP at 28 weeks was 
not significantly different in the metformin and placebo group.  
 
 
 
 
 Metformin group 
(n=59)  
Mean (± SD) a 
Median (IQR) b 
Placebo group 
(n=59)  
Mean (± SD) a 
Median (IQR) b 
P 
value 
Baseline fasting insulin 
(pmol/l),  
106.1(± 56.2) 105.3 (± 53.2) 0.9a 
Baseline insulin 
resistance (HOMA-IR 
score),  
1.88 (± 0.95) 1.88 (± 0.91) 1.00a 
Baseline C-reactive 
protein(mg/l),  
10.85 (7.1-16.6) 11.8 (7.9-18) 0.4b 
Fasting insulin at 28 
weeks (pmol/l),  
(n=25)                                                                
95 (71-121) 
(n=18)
158.5 (102.8-195) 
<0.05b 
Insulin resistance at 28 
wks (HOMA-IR score),  
1.98 (1.29-2.2) 2.81 (1.92-3.72) 0.03b 
C-reactive protein at 28 
weeks (mg/l),  
9.4 (5.6-14.4) 11.7 (7.4-21.9) 0.1b 
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Figure 3-5: Insulin resistance (HOMA-IR) at recruit and at 28 weeks in the 
metformin and placebo groups 
MF-IR-R – HOMA-IR in the metformin group at recruitment, MF-IR-28 – HOMA-IR in the 
metformin group at 28 weeks, Pl-IR-R – HOMA-IR in the placebo group at recruitment, Pl-IR-28 
– HOMA-IR in the placebo group at 28 weeks. Women in the metformin group showed a lesser 
increase in HOMA-IR at 28 weeks from recruitment as compared to the placebo group.  
Table 3-8 shows independent samples t-test for differences in means between 
those on metformin and those on placebo. The change in values between 28 
weeks and baseline for fasting insulin, insulin resistance (HOMA-IR), CRP, VFM 
at term and postnatal, was calculated in both the metformin and placebo 
groups. The mean of the changes for all these variables was determined for 
each group. The difference in mean change (28 weeks – baseline) for fasting 
insulin between the metformin and the placebo group is - 47.8 (P=0.007) and 
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for insulin resistance was -.76 (P=0.04). There was a no significant difference in 
change in CRP at any of the measurement time points. There was a significant 
difference in mean change in VFM at term (-6.9, P=0.03) and postnatal (-8.2, 
P=0.01), compared to baseline between the two groups. There was a 50.5% 
increase in fasting insulin concentration and a 49.4% rise in insulin resistance 
from booking to 28 weeks of pregnancy in the group of women receiving 
placebo. However, there was only a 5.3% rise in insulin resistance at 28 weeks 
in the metformin group.  
Table 3-8: t-test for equality of means- Difference in fasting insulin, insulin 
resistance, VFM and CRP at 28 weeks to baseline compared between treatments 
 t-test for Equality of Means 
Significance      
(2-tailed) 
 
Mean 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Change in fasting insulin 
(28wks – baseline) <0.05 -47.8 -81.5 -14.1 
Change in insulin resistance 
(28wks – baseline) 0.04 -.76 -1.46 -.05 
Change in CRP (28 weeks- 
baseline) 0.1 -2.68 -5.98 .62 
Change in VFM (term-
baseline) 0.03 -6.9 -13.09 -.77 
Change in VFM (postnatal-
baseline) 0.01 -8.2 -14.63 -1.82 
Mean difference – average difference between readings, Sig (2 tailed) – equivalent to P value  
(<0.05 denotes significant difference), 95 % Confidence interval of the difference – range within 
which true mean difference lies (95% confident) 
Pregnancy induced hypertension and preeclampsia were not significantly 
different in the two groups. Similarly, the rates of CS were also not significantly 
different in the groups (44.1% in the metformin group vs. 40.7% in the placebo 
group; P=0.8). There was a trend towards a lower incidence of GDM in the 
metformin group as compared to the placebo group. However, the difference 
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did not reach statistical significance (6 [10.2%] versus 11[18.6%], P=0.3) (Table 
3-9). 
Table 3-9: Maternal pregnancy outcomes - statistical comparison between 
metformin and placebo groups 
a 
Fisher‟s exact Test. PIH, PET were not significantly different between groups. There was also 
no significant difference in the number of women delivering by Caesarean section between the 
two groups. Lesser women in the metformin group developed GDM as compared to the placebo 
group although this difference did not reach statistical significance. 
There was a trend towards higher baseline HOMA-IR in the 16 women who 
developed GDM than in women without GDM (1.82 [1.4-2.5] vs. 1.68 [1.3-2.4], 
P=0.6). However, this difference did not reach statistical significance (Table 
3-10).    
Table 3-10: Baseline HOMA-IR in women with GDM and no GDM 
 
GDM (n=16) 
Median (IQR)  
No GDM (n=98) 
Median (IQR)  
 
P value a 
Baseline HOMA-IR 1.82 (1.4-2.5) 1.68 (1.3-2.4) 0.6 
IQR-interquartile range,  
a 
Mann-Whitney U test. 
Five women in the metformin group and 4 women in the placebo group 
developed pregnancy-induced hypertension. Three women in the placebo group 
 
Metformin 
(n=59) 
Placebo 
(n=59) 
P value a 
Pregnancy induced hypertension 
n, (%) 
 
5 (8.5) 
 
4 (6.8) 
 
0.72                   
Preeclampsia n, (%) 0 3 (5) 0.2 
Mode of delivery n, (%) 
Vaginal 
Instrumental 
Elective C/section 
Emergency C/section 
 
 
 
 
 
31 
 2 
9 
17 
 
 
 
31                       
4                 
13 
11                                     
 
1.0 
0.4 
0.5 
0.3 
 
Gestational Diabetes, n (%) 6 (10.2) 11(18.6)  0.3 
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developed preeclampsia compared to none in the metformin group (P=0.2). The 
baseline HOMA-IR was similar in those developing preeclampsia compared to 
those who did not (1.63 units [1.5-2.6] vs. 1.69 units [1.3-2.4], P=0.5). There 
was a trend towards a higher GWG in women who developed preeclampsia, 
compared to women who did not, but the difference was not significant (10.8 kg 
[7.1-12.8] vs. 6.8 kg [4-8.7], P=0.3) (Table 3-11).  
Table 3-11: HOMA-IR in women with preeclampsia 
IQR-interquartile range,  
a 
Mann-Whitney U test. 
There was no significant difference between the metformin group and the 
placebo group in the median neonatal birth-weight z score. The distribution of 
the baby birth weight was normal and hence is presented as mean ± SD. The 
mean birth weight in the two groups were not significantly different (3421± 564 g 
vs. 3374 g ± 876; P=0.7). There was no significant difference in the mean birth 
centile between the two groups (52.3 ± 30.8 vs. 53.0 ± 30.4; P=0.8). Similarly, 
the   percentage of large for gestational age babies (LGA) was similar in both 
groups (20.3% vs. 18.6%, P=1). There was also no significant difference in the 
rate of admission to neonatal care units (5.1% vs. 3.4%, P=1), neonatal 
jaundice (3.4% vs. 5.1%, P=1), neonatal hypoglycaemia (5.1% vs. 3.4%, P=1) 
and shoulder dystocia (0% vs. 0%; P=1) in both the groups (Table 3-12). 
 
 
 
Preeclampsia 
(n=3) 
Median (IQR) 
No Preeclampsia 
(n=111) 
Median (IQR) 
 
P value a 
HOMA-insulin 
resistance, units 
1.63 (1.5-1.6) 1.69 (1.3-2.4) 0.5 
Gestational weight gain, 
kg  
10.8 (7.1-12.8) 6.8 (4-8.7) 0.3 
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Table 3-12: Neonatal outcomes-statistical comparison between the metformin or 
placebo groups 
a
 Independent two samples t-test, 
b
 Mann- Whitney U test, 
c 
Fisher‟s exact test, 
d
 Capillary 
glucose <2.6mmol/l . There was no significant difference in any of the neonatal outcomes. 
I stratified the women into two groups according to the baseline insulin 
resistance, those with baseline insulin resistance ≥ 75th percentile and others 
with insulin resistance < 75th percentile. In the metformin group, only 1 women 
of the 15 with baseline insulin resistance ≥ 75th percentile developed GDM. In 
the placebo group, 4 of the 9 women with baseline insulin resistance ≥ 75th 
percentile developed GDM. In the group of women with baseline insulin 
 Metformin group 
(n=59)           
Mean (± SD) a        
Median(IQR) b  
 
Placebo group 
(n=59)         
Mean (± SD) a 
Median(IQR) b  
 
P value 
Median birth-weight z 
score (IQR) 
0.0 (-0.7 - 0.7) 0.1(-0.5 - 0.8) 0.9 b 
Birth-weight (gram), mean 
± SD  
3421 ± 564 3374 ± 876 0.7 a 
BW Centile, mean ± SD  52.3 ± 30.8 53.0 ± 30.4 0.8 a 
BW centile > 90, n (%) 12 (20.3) 11(18.6) 1c 
BW centile < 10, n (%) 6 (10.2) 10(16.9) 0.4 c 
Preterm < 37 weeks, n (%) 4(6.8) 4(6.8) 1.0c 
Jaundice requiring 
phototherapy, n (%) 
2(3.4) 3(5.1) 0.65c  
Hypoglycaemia d, n (%) 3(5.1) 2(3.4) 0.65c 
Neonatal unit admissions, 
n (%) 
3(5.1) 2(3.4) 0.65c 
Shoulder dystocia, n (%) 0 0 1.0c 
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resistance < 75th percentile, there was not much difference in the incidence of 
GDM between the groups (Table 3-13).  
When comparing the risk of GDM in the placebo group alone, stratified by 
HOMA IR, four out of 9 women (44.4%) with baseline HOMA-IR ≥ 75th 
percentile developed GDM, whereas, only six of the forty eight women (12.5%) 
with HOMA IR ≤ 75th percentile developed GDM. 
Table 3-13: GDM incidence according to baseline insulin resistance in the 
metformin and placebo groups  
                                                                                        
Only 1 woman with baseline insulin resistance ≥ 75
th
 percentile randomised to metformin   
developed GDM out of 15 women compared to 4 women from the placebo group developing 
GDM out of 9 women in the group with baseline insulin resistance < 75
th
 percentile.  
 
I calculated the odds ratio to estimate the risk of GDM. In the group with 
baseline insulin resistance ≥ 75th percentile, the OR was 0.09; this suggests that 
the metformin group are much less likely to develop GDM than the placebo 
group. However, the 95% confidence interval puts the risk somewhere between 
0.008 and 1.0016, indicating that the difference in risk between the two groups 
is not statistically significant (Table 3-14). 
 
 Metformin  
(n=59) 
Placebo  
(n=59) 
 
 
Baseline insulin resistance > 75th 
percentile, n (%) 
 
                   developed GDM, n (%) 
 
 
15 (26.8) 
                          
 
1(6.6) 
 
9 (15.8)                                                            
 
 
4 (44.4) 
 
 
 
Baseline insulin resistance < 75th 
percentile, n (%) 
 
                  developed GDM, n (%) 
 
 
41 (73.2) 
 
5 (12.2) 
 
48 (84.2) 
 
6 (12.5) 
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Table 3-14: Estimates of relative risk of GDM between metformin and placebo 
groups in women with baseline insulin resistance ≥ 75th percentile 
Estimates of the Relative Risk (Row1/Row2) 
Type of Study Value 95% Confidence Limits 
Case-Control (Odds Ratio) 0.09 0.0080 1.0016 
    
The odds ratio between the 2 groups was 0.09 suggesting that women randomised to metformin 
are less likely to develop GDM. However, this was not statistically significant. 
In the group with baseline insulin resistance group < 75th percentile, the OR is 
0.97. This suggests that the metformin group are more or less just as likely to 
develop GDM as the placebo group. The 95% confidence interval puts the risk 
somewhere between 0.27 and 3.45, indicating that the difference in risk 
between the two groups is not statistically significant (Table 3-15). 
 
Table 3-15: Estimates of relative risk of GDM between metformin and placebo 
groups in women with insulin resistance < 75th percentile 
The odds ratio between the 2 groups is 0.97 suggesting that women randomised to metformin 
were more or less just as likely to develop GDM. 
Similarly, when both groups, women with insulin resistance > 75th percentile 
and women with insulin resistance < 75th percentile, were considered together 
the OR was 0.54. This suggests that the metformin group are less likely to 
develop GDM than the placebo group, but the 95% confidence interval puts the 
risk somewhere between 0.19 and 1.55, indicating that the difference in risk 
between the two treatment groups was not statistically significant (Table 3-16). 
 
Estimates of the Relative Risk (Row1/Row2) 
Type of Study Value 95% Confidence Limits 
Case-Control (Odds Ratio) 0.97                                     0.2737-3.4535 
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Table 3-16: Estimates of relative risk of GDM between metformin and placebo 
groups in women when both groups were considered together 
 
 
The odds ratio between the 2 groups was 0.5394 suggesting that women randomised to 
metformin were less likely to develop GDM. However, the 95% confidence interval is between 
0.19 and 1.55, which was not statistically significant. 
 
I used the Breslow–Day test to compare the risks of GDM in the two groups, but 
the difference was not statistically significant at 5% (P=0.07) (Table 3-17). 
Table 3-17: Breslow-Day test for homogeneity of the Odds Ratios 
Breslow-Day Test  
Chi-Square 3.2831 
DF 1 
Pr > ChiSq 0.07 
 
The graph below (Figure 3-6) also indicates that there was no significant 
difference in the risk of developing GDM in patients taking metformin between 
the high and low insulin groups, as confidence intervals for the risks overlap. 
 
 
Estimates of the Common Relative Risk (Row1/Row2) 
Type of Study                               Method     Value                95% Confidence Limits 
Case-Control (Odds Ratio) Mantel-
Haenszel                    
                  0.54                0.1876- 1.5515 
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Figure 3-6 Odds ratio of developing GDM with 95% confidence limits in the high 
and low insulin resistance groups 
The confidence intervals for the risk of developing GDM overlapped between the high insulin 
resistance group and the low insulin resistance group indicating there was no significant 
difference in the risk of developing GDM between the two groups 
The GWG was significantly reduced in women receiving metformin (3.9 kg vs. 7 
kg, P<0.05). When stratified by baseline insulin resistance, GWG was 
significantly reduced by metformin in women with HOMA-IR greater than 75th 
percentile (3.1 ± 0.6 kg vs. 6.6 ± 2.5 kg, P<0.05) and also in those with baseline 
HOMA-IR values less than 75th percentile (4.6 ± 4.5 kg vs. 6.9 ± 4.9 kg, 
P=0.02). No correlation was found between GWG and HOMA-IR in the 
metformin (r=-0.15) and placebo (r=-0.15) groups. 
The result of baseline HOMA-IR ≥ 75 percentile were significantly more likely 
among those who subsequently developed GDM, compared with women who 
did not develop GDM in the placebo group. The odds ratio was 5.7 (95% 
confidence interval 1.2-27.5), p=0.02 (Table 3-18). 
However, there was no such association seen with pregnancy-induced 
hypertension and preeclampsia. The number of patients with HOMA-IR ≥ 90th 
percentile was very small (n=5). Of these 5 women, one developed GDM and 
PIH and another women developed preeclampsia. 
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Table 3-18: Baseline HOMA-IR and risk of subsequent GDM, PIH and PET in the 
placebo group 
a 
n=10 women who developed GDM in the placebo group 
b
 n=48 women who did not develop GDM in the placebo group 
c
 n=4 women who developed PIH in the placebo group 
d
 n=54 women who did not develop PIH in the placebo group 
e
 n=3 women who developed PET in the placebo group 
f
 n=55 women who did not develop PET in the placebo group 
Adverse Events 
There was no significant difference in the incidence of SAE between the groups, 
but the incidence of side effects like nausea, vomiting and diarrhoea were 
higher in the metformin group as compared to the placebo group. Eleven 
patients receiving metformin and four receiving placebo complained of nausea 
and vomiting. Similarly, more patients in the metformin group complained of 
diarrhoea (nine patients) as compared to the placebo group (two patients). One 
patient from the metformin group was admitted overnight with diarrhoea (Table 
3-19). In three patients, one in the metformin group and two in the placebo 
group, fetal scan showed fetal growth restriction with estimated fetal weight < 
5th percentile and abnormal fetal Doppler studies. The trial medications were 
stopped in these patients as per protocol guidelines.  
 
 
 
 
  Odds ratio 
(95%CI) 
P value 
 
 
 
Baseline 
HOMA IR ≥ 75th 
percentile, n=9 
 
 
GDM, %a 
40 
No GDM, %b
 
10.4 
 
                       
5.7 (1.2-27.5) 
        
0.02 
 
PIH, %c 
25 
No PIH, %d
 
14.8% 
 
                      
1.9 (0.17-20.8) 
          
0.5 
PET, %e 
0  
No PET, %f
 
16.3% 
 
                      
0.7 (0.03-14.7) 
          
0.8 
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Table 3-19: Comparison of side-effects in the metformin and placebo groups 
Side effects Metformin Placebo P value  
At least one side effect, n (%) 27 (45.8) 10 (16.9) <0.05 
Nausea and vomiting, n (%) 11 (18.6) 4 (6.8) 0.09 
Diarrhoea, n (%) 9 (15.3) 2 (3.4) 0.05 
Abdominal pain or heartburn, n (%) 4 (6.8) 4 (6.8) 1.0 
Consequences of side-effects    
                            Stopped tablets, n (%) 2 (7.4) 2 (20) 0.3 
                            Reduced dose, n (%) 15 (55.6) 5 (50) 0.76 
                            Continued dose, n (%) 10 (37) 3 (30) 0.99 
a 
Fishers exact test 
Adherence to the study regimen was assessed as good (> 50% of tablets 
taken) in 97 (82.2%) of the 118 participants and poor (< 50% of tablets taken) in 
21 (17.8%). The adherence was poor in 10 women receiving metformin and 11 
women receiving placebo. The maximum daily tolerated dose of 
metformin/placebo was 3 g.  There was no significant difference in degree of 
compliance between subjects receiving metformin or placebo. The percentage 
of women taking ≥ 2500 mg of metformin per day was an overall 88.1%.  
There was no significant difference in the anthropometric measurements at birth 
in the neonates of mothers receiving metformin or placebo (Table 3-20). 
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Table 3-20: Comparison of neonatal anthropometric measurements between the 
metformin and placebo groups. 
a 
Mann-Whitney U test, There is no difference in the neonatal anthropometric measurements 
between the two groups. 
 
3.7 DISCUSSION 
 
The results of the study showed that in obese, non-diabetic pregnant women 
with BMI ≥ 35 kg/m2, treatment with metformin did not reduce the median 
neonatal birth-weight z score or the incidence of LGA neonates. However, 
metformin therapy reduced GWG, reduced the rise in VFM during pregnancy, 
and attenuated the expected physiological rise in insulin resistance seen at 28 
weeks of gestation. 
Measurements 
Metformin 
Median 
(IQR) 
Placebo 
Median 
(IQR) 
P 
valuea  
Head circumference, cm (n=104) 35 (34-35.8) 34.5 (33-35) 0.1 
Chest circumference, cm, (n=104) 33.5 (32-35) 34 (32.8-35) 0.5 
Abdominal circumference, cm, n=104) 32 (30-33.5) 32 (30-34) 0.9 
Length, cm,(n=104) 51 (49.5-53) 52 (49.5-54) 0.3 
Crown-rump length, cm, (n=56) 31 (29-33) 31.5 (30-33) 0.3 
Biceps skin fold, mm, (n=56) 11 (10-11.5) 11 (10-12) 0.06 
Triceps skin fold, mm, (n=56) 5.4 (4.6-6.2) 5.3 (4.9-5.9) 0.8 
Subscapular skinfold, mm, (n=56) 5 (4.4-6) 5.6( 4.9-6.1) 0.5 
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Only 10.2% of the women in the metformin group developed gestational 
diabetes compared with 18.6% in those allocated to placebo, but this difference 
was not significant. Therefore, even though metformin blunted the rise in insulin 
resistance at 28 weeks, the incidence of GDM was not significantly reduced. 
This is probably because some of these women with a high BMI > 35 kg/m2 are 
relatively resistant to the insulin sensitising effects of metformin. Studies in 
women with polycystic ovaries have shown that those who develop GDM are 
more hyperinsulinemic and more insulin resistant [158]. There was a trend for a 
higher baseline insulin resistance in women who developed GDM as compared 
to no-GDM women but again this difference was not significant. This perhaps 
suggests that metformin initiation at 12 weeks of gestation in obese women may 
be a late start and the adverse effects of obesity have already begun. Also, the 
study was not adequately powered for detection of the difference in rate of 
gestational diabetes between groups. 
Women receiving metformin had a significantly lower increase in visceral fat 
compared with those on placebo. Also, the effects of metformin persisted into 
the post-partum period as reflected by the greater reduction in visceral fat and 
lower VFM after delivery in this group. This effect may be potentially beneficial 
in reducing the risk for future T2DM and cardiovascular disorders in these 
women.  Visceral fat is associated with insulin resistance and the metabolic 
abnormalities associated with obesity, known as the „metabolic syndrome‟ [111]. 
Visceral fat is also associated with subclinical inflammation and markers of 
inflammation  including CRP are reported to be higher in obese pregnant 
women compared to controls [159]. There was a trend towards a lower CRP at 
28 weeks in the metformin group as compared to the placebo group, but this 
difference was not statistically significant. 
There was no significant difference in the incidence of pregnancy-induced 
hypertension between the two groups. Three women developed preeclampsia 
in the placebo group compared to none in the metformin group. The baseline 
insulin resistance in the group of women developing PIH or preeclampsia was 
similar to the women who did not develop PIH or preeclampsia. There was a 
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trend towards a higher GWG in women who developed preeclampsia as 
compared to women who did not. The greater GWG could also contribute to the 
increased incidence of preeclampsia. Previous studies have shown that the 
prevalence of preeclampsia increased, both with increasing pre pregnancy BMI 
and increasing gestational weight gain [88][160]. The decrease in GWG seen in 
women on metformin could be multifactorial and is closely related to decreased 
food intake [161]. 
No significant differences were found comparing metformin or placebo treated 
patients in relation to mode of delivery, neonatal jaundice, neonatal 
hypoglycaemia, admission to SCBU, shoulder dystocia.  
One of the aims of the study was also to determine whether there is an 
association between baseline insulin resistance and adverse pregnancy 
outcomes such as gestational diabetes, pregnancy-induced hypertension and 
preeclampsia. When comparing the risk of GDM stratified by HOMA IR in the 
placebo group alone, four out of 9 women (44.4%) with baseline HOMA-IR ≥ 
75th percentile developed GDM whereas only six of the forty eight women 
(12.5%) with HOMA IR ≤ 75th percentile developed GDM (P=0.04). Also, there 
was a significant association with baseline HOMA-IR ≥ 75th percentile and 
subsequent GDM [Odds Ratio (CI), 5.7 (1.2-27.5)]. This suggests that women 
with high baseline insulin resistance have a higher risk of developing GDM. 
There was no such association of high baseline insulin resistance with PIH or 
preeclampsia in the placebo group. However, the overall rate of preeclampsia is 
very low in our study and hence it is difficult to comment.  
The study also aimed to examine the hypothesis that metformin is most 
effective in those patients with the highest baseline insulin resistance and 
treatment with metformin throughout pregnancy will reduce the risk of 
gestational diabetes in this group of women. When stratified by insulin 
resistance, there was a trend towards a lower risk of GDM for women in the 
high IR group receiving metformin as compared to placebo. One of the fifteen 
women with high HOMA-IR randomised to metformin developed GDM 
compared with four of the nine with high HOMA-IR randomised to placebo.  
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However, there was no statistically significant difference between the groups. 
Therefore, the hypothesis that metformin is most effective in women with 
highest baseline insulin resistance in preventing GDM, is not substantiated by 
the study results. 
There was no significant difference in the incidence of SAE between the groups 
but the incidence of side effects like nausea, vomiting and diarrhoea was higher 
in the metformin group as compared to the placebo group. Despite this, 
adherence to the study regimen was assessed as good in 82.2% of the 
participants.  
There was also no difference in the neonatal anthropometric measurements at 
birth in both the groups. The MiG TOFU study has shown a more favourable 
pattern of fat distribution in two year old children of mothers who had received 
metformin in pregnancy [127]. However, in that study, the comparison was 
between neonates of mothers randomised to metformin or insulin. There was no 
long term follow up of the babies born to mothers who participated in the MOP 
Trial. 
Genetic polymorphisms in drug uptake transporter genes have been 
increasingly recognised as a possible mechanism accounting for variation in 
metformin response [162] . It has also become increasingly clear that the 
pharmacokinetics of metformin are primarily determined by membrane 
transporters, including the plasma membrane monoamine transporter (PMAT), 
the organic cation transporter (OCTs), the multidrug and toxin extrusion-1 
transporter (MATE-1) and the critical AMPK [162]. Some genetic variants of 
membrane transporters have been proved to determine the pharmacokinetics of 
metformin and a differential response after treatment in obese subjects e.g. the 
glucokinase regulatory protein (GCKR), the peroxisome proliferator activated 
receptor gamma, coactivator 1 alpha (PPARGC1A) and the fat mass and 
obesity associated protein (FTO gene) [163]. The GoDARTS and UKPDS 
metformin pharmacogenetics study groups investigated the genetics of 
metformin response in a discovery cohort of 1024 Scottish individuals with type 
2 diabetes and incident metformin use. A locus on chromosome 11, tagged by 
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rs11212617 was associated with metformin response. Although promising, this 
locus only explains 2.5% of the variance in metformin response [164].  
Comparison with other relevant studies 
There are very few studies published to date which quantitate the effect of 
metformin on insulin resistance in pregnancy. The mean HOMA-IR score 
measured at 28 weeks in the placebo group (3.07 ± 1.7) in my study was similar 
to the insulin resistance measurements in the standard care group of the 
UPBEAT study [113] (3.04 ± 2.1, P=NS) [20] and the control group of the LiP 
study (3.4 ± 1.8, P=NS) [112], described earlier. The MOP trial showed a 59.8% 
increase in the fasting insulin concentration at 28 weeks of gestation in the 
placebo group. This was similar to a previous study which showed 65% 
increase in fasting insulin concentration in the control group during pregnancy 
[165]. There was only a 5.3% increase in insulin resistance in the metformin 
group at 28 weeks of gestation, whereas in the placebo group, there was a 
49.4% increase in insulin resistance. Glueck et al. reported a 4.4% decrease in 
HOMA-IR score at 28 weeks of gestation in women with polycystic ovaries 
treated with metformin in pregnancy [133]. This effect of metformin in 
attenuating the rise in HOMA-IR normally seen at 28 weeks of pregnancy was 
also observed in the EMPOWaR trial [114]. 
Women allocated to metformin gained considerably less weight during 
pregnancy.  The gestational weight gain in the placebo group was similar to that 
reported in the standard care group participants of the UPBEAT study (7.76 ± 
4.6 vs. 7 ± 4.5; NS) [113] and the intervention group of the LiP study (7 ± 4.5 vs. 
7.4 ± 4.6, P=NS) [147]. This suggests that the lifestyle intervention used in the 
MOP trial in the entire cohort was effective and comparable to that reported in 
previous lifestyle intervention studies. The instant read-out of results from the 
InBody 720 bio impedance device at each antenatal clinic visit served as a very 
effective motivational tool helping to avoid excessive weight gain.  
There was a trend towards a decrease in CRP levels in women on metformin 
and a similar finding was reported in the EMPOWaR trial [114]  and in non-
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pregnant adults treated with metformin in the Diabetes Prevention Program 
[159].   
There are a few studies investigating the effect of metformin on pregnancy 
outcomes in women with polycystic ovary syndrome [154][155][166][167]. Most 
studies show that metformin has no significant effect on neonatal birth weight or 
on the incidence of preeclampsia or GDM. One study using a dose of metformin 
of 2000 mg per day, shows  significantly less maternal weight gain compared to 
placebo [166]. Another trial on 40 women shows that metformin is associated 
with a significantly lower rate of preeclampsia than placebo[167]. Studies in 
women with polycystic ovaries, which is characterised by insulin resistance, 
also suggest that obese women are either refractory to the effects of metformin 
or may require increased dosage[168][169].  
The EMPOWaR trial showed no significant differences in the median birth 
weight, maternal GWG, the rate of preeclampsia or the rate of adverse perinatal 
events between the metformin and the placebo groups. Only Caucasians were 
included in this study unlike in the MOP trial in which all races were included, so 
that the results can be extrapolated to the whole population. The MOP trial used 
the higher cut off point for BMI at 35 kg/m2 instead of 30 kg/m2 used in 
EMPOWaR, in order to have adequate power with a smaller sample size. The 
adherence to the study regimen was also higher in the MOP trial with nearly 
80% of women having taken at least 50% of the total number of tablets 
prescribed. In the EMPOWaR study, women were considered to have adhered 
to the study regimen if they took a minimum of 1 tablet of 500 g for at least 29% 
of the days and only 67% fulfilled these criteria [114].  
The strengths of the MOP Trial were its randomised controlled design, the 
racially heterogeneous nature of the participating group of women, the high 
percentage of eligible women who agreed to participate and high levels of 
compliance with study medication. A limitation of it is that it was not adequately 
powered for the secondary outcomes like gestational diabetes and 
preeclampsia. The number of women with high insulin resistance in each study 
group was very small making comparisons difficult to interpret. Future studies 
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should also examine body composition in the offspring of mothers receiving 
metformin as evidence of benefit in childhood fat distribution is beginning to 
emerge [127]. 
Comparison of the St Helier cohort with the entire MOP Trial 
The results of the St Helier cohort  of the MOP trial are essentially similar to the 
results seen in the entire MOP trial (n=450), reported in the New England 
Journal of Medicine (NEJM) in February 2016 [134]. There were no significant 
differences between the metformin and the placebo groups in neonatal birth 
weight z score, incidence of LGA neonates or adverse fetal or neonatal 
outcomes. In the entire MOP trial, the incidence of preeclampsia was 
significantly lower in the metformin group than in the placebo group (3.0% vs. 
11.3%; odds ratio 0.24; 95% confidence interval, 0.10 to 0.61; p=0.001) [134]. 
This effect was not seen in our St Helier cohort as I had only 3 cases of 
preeclampsia in my study and all were in women from the placebo arm. I 
conducted a secondary analysis to examine whether the reduced incidence of 
preeclampsia in women treated with metformin in the entire MOP trial is 
mediated by changes in insulin resistance [170]. The results of the analysis 
showed that median HOMA-IR was significantly lower in the metformin group at 
28 weeks of gestation. Logistic regression analysis demonstrated that there was 
a significant contribution in the prediction of preeclampsia from maternal history 
of chronic hypertension and gestational weight gain, but not HOMA-IR either at 
randomisation (p=0.514) or at 28 weeks (p=0.643). The study concluded that 
the reduced incidence of preeclampsia in non-diabetic obese pregnant women 
treated with metformin is unlikely to be due to changes in insulin resistance 
[170]. Metformin could have a potential benefit in reducing the risk of 
preeclampsia because of its modulatory effect on endothelial dysfunction.  
In summary, my cohort showed that metformin given to non-diabetic obese 
pregnant women from 12-18 weeks of gestation until delivery, did not reduce 
the neonatal birth weight centile or the incidence of LGA babies. However, 
metformin therapy reduced GWG, reduced the rise in VFM during pregnancy, 
and attenuated the expected physiological rise in insulin resistance seen at 28 
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weeks of gestation. Surprisingly, this did not lead to an overall significant 
reduction in the incidence of gestational diabetes or have a beneficial effect on 
other pregnancy outcomes such as the incidence of macrosomic babies. The 
study showed a trend towards a reduction in gestational diabetes in obese 
pregnant women with high baseline insulin resistance randomised to metformin 
as compared to placebo. However, these differences are not statistically 
significant. Similarly, there appears to be a potential effect of metformin in 
reducing preeclampsia, though the number of women developing preeclampsia 
in the St Helier cohort was very small. My study was not powered for the 
secondary outcomes like GDM and preeclampsia and larger studies of 
metformin in obese pregnant women in pregnancy are warranted. 
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4     DISCUSSION AND CONCLUSIONS 
The CEMACH in its 2003-2005 triennia report has highlighted obesity in 
pregnancy as a cause for increased morbidity and mortality in mother and baby 
[67]. The literature review showed that obesity is associated with a number of 
serious adverse outcomes including GDM and preeclampsia [68][151]. The 
prevalence of GDM is rising and this is concerning because of the risk of 
pregnancy complications such as macrosomia, shoulder dystocia, Caesarean 
section and neonatal hypoglycaemia and also because of the risk to the mother 
and offspring of diabetes and cardiovascular disease in later life [68][104] [131].  
The literature search did not reveal any published studies that investigated VFM 
as a risk factor for adverse pregnancy outcomes in obese women. Therefore, to 
my knowledge, the VFM study was the first study examining the role of VFM in 
determining pregnancy and neonatal outcomes in obese women. 
The results of the VFM study showed that baseline VFM is a novel risk factor for 
GDM. There was clearly a significant association between higher baseline VFM 
(≥ 75th percentile) and risk of subsequent GDM. Obese women with a baseline 
VFM ≥ 75 percentile had a 3-fold risk of GDM. There was a correlation between 
VFM and fasting glucose and HbA1c in all women who developed GDM. Similar 
correlations of VFM with fasting hyperglycaemia and HbA1c have been shown in 
patients with T2DM [110].  This suggests that visceral rather than non-visceral 
subcutaneous fat has a metabolic effect [143][144]. In the general population, it 
is already well-established that excess visceral fat and insulin resistance, but 
not general adiposity, are independently associated with pre-diabetes and 
T2DM in obese adults [107] [108]. Body fat composition measurements by 
InBody are easy to perform, take less than 5 minutes per test and are non-
expensive.  
To the best of my knowledge, this was also the first attempt to create a 
mathematical model to predict GDM and LGA baby using VFM. PCA failed to 
classify GDM correctly. Hence, supervised learning methods were applied to 
design and develop a predictive model using random forest and decision tree 
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modelling. The mathematical model managed to predict GDM with an average 
prediction accuracy of 77.5%. However, the model got better trained in 
detection of no-GDM than GDM. The birth centile model could correctly predict 
birth centile classes with an average of 68%. The model was well trained in 
predicting normal birth centiles but not as accurate in predicting low or high birth 
centiles. As I discussed earlier, GDM and fetal macrosomia could be considered 
a metabolic complication of diabetes like macrovascular disease rather than a 
microvascular complication of diabetes. Hence, it would be very important to 
predict the risk of macrosomia with the birth centile model. 
The current method of screening for GDM is based on the presence of clinical 
risk factors which provides a detection rate of approximately 60% with a 40% 
false positive rate [125]. Currently, those women identified with even a single 
risk factor undergo an oral glucose tolerance test at 24-28 weeks gestation. 
Risk stratification for GDM early in pregnancy may reduce the need for OGTT in 
women at low risk, resulting in savings in costs and in healthcare personnel 
time. It could also help to avoid extra clinic visits and extra scans in low risk 
obese women. In current settings, by the time GDM is diagnosed at 28 weeks of 
gestation, the effects of hyperglycaemia on the fetus may be already evident on 
the ultrasound growth scans. Conversely those at high risk can start lifestyle 
interventions early to reduce the risk of complications.    
Lifestyle intervention programmes in pregnancy have shown no beneficial 
effects on the neonate [113][147][148][149]. Since insulin resistance is 
increased in obesity, and obesity is strongly associated with birth weight and 
fetal adiposity [131], metformin, an insulin sensitiser, was a rational choice for 
the MOP trial. The results of the St Helier cohort of the MOP trial showed that in 
obese, non-diabetic pregnant women, treatment with metformin did not reduce 
the median neonatal birth weight z score, incidence of LGA neonates or other 
adverse fetal and neonatal outcomes. However, metformin therapy reduced 
GWG, reduced the rise in visceral fat mass during pregnancy and attenuated 
the expected physiological rise in insulin resistance seen at 28 weeks of 
gestation. 10.2% of the women in the metformin group developed gestational 
 114 
diabetes compared with 18.6% in those allocated to placebo, but this difference 
was not significant. Therefore, even though metformin blunted the rise in insulin 
resistance at 28 weeks, the incidence of GDM was not significantly reduced.  
There was a trend for a higher baseline insulin resistance in women who 
developed GDM as compared to no-GDM women but again this difference was 
not significant. This raises the question whether the metformin initiation at 12 
weeks of gestation in the MOP trial was a delayed intervention, and the adverse 
effects of obesity on the fetus had already set in.  
There was a significant reduction in the GWG in the metformin group. Women 
receiving metformin had a significantly lesser increase in visceral fat at term, 
compared with those on placebo. Also, these effects persisted into the post-
partum period. This may be potentially beneficial in reducing the risk for future 
T2DM and cardiovascular disorders in these women. 
In the placebo group alone, more women with baseline HOMA-IR ≥ 75th 
percentile developed GDM, compared to women with HOMA IR ≤ 75th 
percentile (44.4% vs. 12.5%, P=0.04). Also, there was a significant association 
with baseline HOMA-IR ≥ 75th percentile and subsequent GDM [Odds Ratio 
(CI), 5.7 (1.2-27.5)]. This suggests that women with high baseline insulin 
resistance have a higher risk of developing GDM. There was no such 
association of high baseline insulin resistance with PIH or preeclampsia in the 
placebo group. However, the overall rate of preeclampsia is very low in our 
study and hence it is difficult to comment.  
The hypothesis that metformin is most effective in women with highest baseline 
insulin resistance in preventing GDM, was not substantiated by the study 
results. When stratified by insulin resistance, there was a trend towards a lower 
risk of GDM for women in the high IR group receiving metformin as compared to 
placebo. This difference again was not significant.  
The strengths of the MOP trial were its randomised controlled design, the 
racially heterogeneous nature of the participating group of women, and high 
levels of compliance with study medication. A limitation was that it was not 
adequately powered for the secondary outcomes like gestational diabetes and 
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preeclampsia. Also, the number of women with high insulin resistance in each 
study group was very small, making comparisons difficult to interpret.  
There was a MHRA inspection of the MOP trial at St Helier Hospital. They 
checked the intricate details of the conduct of the trial and were satisfied that 
the trial was conducted in accordance to the Good Clinical Practice guidelines. 
The mechanisms responsible for adverse pregnancy outcomes in obesity may 
be mediated by several metabolic pathways besides glucose [171]. Maternal 
blood glucose is subtly increased among obese women. The HAPO study has 
shown that even modest increments can influence fetal growth and adiposity. 
Other important parameters include raised maternal triglycerides and fatty 
acids. Obese mothers have a more atherogenic lipid profile in early pregnancy 
compared to normal weight women and this may influence placentation and be 
the link to adverse pregnancy complications like preeclampsia [172]. Maternal 
insulin resistance contributes to plasma lipid perturbations due to an increase in 
adipose tissue lipolysis. Increased lipolysis provides a surplus of plasma free 
fatty acid substrates for hepatic triglyceride synthesis. These physiologic 
adaptations in pregnancy may differ between normal weight and obese women 
[172]. Recent studies have shown that women who developed GDM had 
significantly increased triglycerides, cholesterol, LDL concentrations, LDL/HDL 
ratios and decreased HDL concentrations in early pregnancy compared to 
controls [173]. One study demonstrated that circulating maternal lipids, but not 
glucose, correlate with fetal growth at different time points during the 3rd 
trimester in a population of well-controlled GDM pregnancies [174]. In this 
study, they found that maternal triglycerides and free fatty acids correlated with 
fetal abdominal circumference at 28 weeks, and at delivery they correlated with 
neonatal birth weight, BMI and fat mass [174]. 
The mechanism for the association between early pregnancy maternal 
dyslipidaemia and GDM risk is unknown. Triglyceride concentrations increase in 
pregnancy to two or three times the nonpregnant levels [175]. This is probably a 
result of increased adipose tissue lipolysis as a consequence of insulin 
resistance and enhanced non esterified fatty acid (NEFA) delivery to the liver 
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which is then associated with increased very low density lipoprotein 
concentrations [175][176]. Reduced lipoprotein lipase activity leads to a reduced 
capacity for triglyceride removal from the circulation [175]. Maternal 
hypertriglyceridemia is associated with maternal insulin resistance [177]. The 
maternal and cord blood leptin concentration is elevated and there is evidence 
of higher levels of CRP and IL-6 in the mother, reflecting a low grade 
inflammatory state. In non-pregnant adults, this elevation of inflammatory 
mediators is linked to insulin resistance [171]. 
Obesity is associated with fetal hyperinsulinemia even in the absence of 
maternal diabetes. Increased influx of amino acids could stimulate fetal 
hyperinsulinemia. Obese women have higher triglyceride levels which could be 
broken down by placental lipases to free fatty acids which could cross the 
placenta. The increased energy influx and fetal hyperinsulinemia together could 
explain macrosomia in obese women without diabetes. 
Besides its anti-hyperglycaemic effect, metformin also causes suppression of 
fatty acid oxidation and a reduction in hypertriglyceridemia. This is associated 
with decreased synthesis and increased clearance of VLDL. Reduction in 
triglyceride levels reduces insulin resistance [14]. Studies have shown that 
(Buchanan et al) mild gestational diabetes is characterised by an impairment of 
β cell function rather than an exaggeration of the normal insulin resistance of 
late pregnancy [24]. Protection against the insulin resistance induced β cell 
failure with metformin could be important.  
In conclusion, this study showed that visceral fat mass is a novel risk factor for 
the development of GDM in obese pregnant women. Obese pregnant women 
with VFM ≥ 75th percentile have a 3-fold higher risk of developing GDM. A 
mathematical model was developed with good overall performance in predicting 
gestational diabetes and LGA babies in these women. To summarise, the 
addition of VFM to conventional risk factors in the predictive model may help 
discriminate between high and low risk pregnancies but this needs to be 
confirmed in larger studies with diverse populations including non-obese 
women. The clinical significance of this model lies in the potential for early and 
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personalised risk stratification for GDM allowing those at high risk to start 
dietary and lifestyle interventions early to reduce the risk of complications. The 
MOP trial showed that metformin given to non-diabetic obese pregnant women 
did not reduce the neonatal birth weight centile or the incidence of LGA babies. 
However, metformin therapy reduced GWG, reduced the rise in VFM during 
pregnancy, and attenuated the expected physiological rise in insulin resistance. 
The study showed a trend towards a reduction in gestational diabetes in obese 
pregnant women with high baseline insulin resistance randomised to metformin 
as compared to placebo.  
 
Future research recommendations 
 A clinical study involving body composition analysis of a larger number of 
obese pregnant women belonging to one ethnicity would provide a large 
training set for the mathematical model to improve its accuracy to predict 
GDM, preeclampsia and LGA babies.   
 Large randomised placebo controlled trial, adequately powered to 
investigate the effect of metformin in reducing GDM and preeclampsia. 
The St Helier cohort of the MOP trial did show a trend towards beneficial 
effects of metformin in decreasing the incidence of GDM in women with 
high baseline insulin resistance, but was not adequately powered to 
comment on these effects of metformin. The entire MOP trial showed 
benefit of metformin in reducing the incidence of preeclampsia, but 
adequately powered studies would be needed to confirm the findings. 
 Future studies should also examine body composition in the offspring of 
mothers receiving metformin, as evidence of benefit in childhood fat 
distribution is beginning to emerge. 
 In the placebo group, baseline HOMA-IR ≥ 75 percentile was a more 
likely finding among those women who subsequently developed GDM, 
compared with women who did not. This suggests that obese pregnant 
women who develop GDM have a high insulin resistance at around 12 
weeks of gestation or perhaps much earlier in pregnancy. Hence, it 
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would be logical that metformin therapy should be started prenatally, 3 
months before conception, to see its effects on prevention of GDM and 
preeclampsia. Future studies should look into prenatal intervention 
programmes, both with lifestyle modification and metformin therapy. 
 Randomised placebo controlled trial to determine if antenatal dietary 
supplementation with Myo-inositol from early pregnancy till delivery will 
reduce the risk of gestational diabetes in obese pregnant women. Myo-
inositol, an isomer of inositol, is a naturally occurring sugar commonly 
found in cereals, corn, legumes and meat. It is one of the intracellular 
mediators of insulin signalling and improves insulin sensitivity. A few 
small studies with Myo-inositol in women with polycystic ovaries have 
shown beneficial effect in preventing gestational diabetes. A large 
number of obese women will have high insulin resistance in early 
pregnancy and may benefit with Myo-ionositol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119 
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2. International Symposium on Diabetes, Hypertension,  
 
Metabolic Syndrome and Pregnancy, Florence, March 2013.  
 
Visceral Fat mass and not total body fat is an adverse prognostic  
 
factor in obese pregnant  women.  
 
           J Balani, S Hyer, A Johnson, H Shehata  
 
3. Diabetes in Pregnancy: National conference, London,  
 
November 2016 - Poster presentation 
 
           A mathematical model for predicting gestational diabetes in obese  
           pregnant women using Machine Learning. 
           Jyoti Balani, Steve Hyer, Hassan Shehata, Fady Mohareb 
 
4. Diabetes in Pregnancy conference, Barcelona, March 2017 
           Insulin resistance, gestational weight gain and incidence of gestational  
           diabetes in obese non-diabetic women receiving metformin. 
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            Chapter 22 in a book on “Obesity”, Elsevier publications  
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This appendix section provides details of the documentation related to ethics for 
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Appendix B Ethics Approval for the MOP Trial 
This appendix section provides details of the documentation related to ethical 
approval for the MOP Trial 
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